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ABSTRACT 
 
Background: Sleeping problems and depression are more common in patients with 
chronic kidney disease (CKD) than the general population. The primary objective of this 
cross-sectional study was to test factors associated with sleep disturbances, depression, 
and quality of life among patients with CKD.  
Methods: We recruited patients with CKD who lived in the St. John’s area from 
September 2012 to December 2012.  The Pittsburgh Sleep Quality Index (PSQI), the 
Berlin Questionnaire (BQ), the Beck Depression Inventory (BDI), the Beck Depression 
Inventory Fast-Screen for Medical Patients (BDI-FS), and the Short Form 36 Quality of 
Life Health Survey Questions (SF-36) were administered to all participants. A chart 
review was performed for the patients’ demographics, diagnoses, medication lists, and 
certain laboratory parameters—including blood glucose, hemoglobin, albumin, calcium, 
phosphate, parathyroid hormone, and estimated glomerular filtration rate (e-GFR). 
Logistic regression models were employed to estimate odds ratios (OR) with 95% 
confidence intervals (CI).  
Results: The sample had a total of 303 patients (41% female and 99% Caucasian). One 
hundred and seventeen (39%) patients were labeled as poor sleepers with the PSQI, while 
157 (51.8%) patients had high risk for sleep apnea in the study cohort. Physical 
component scores (PCS) and mental component scores (MCS) of the SF-36 questionnaire 
were significantly lower in the dialysis group when compared to the non-dialysis group. 
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A higher risk for impaired sleep was associated with being a female and on 
antidepressants and/or benzodiazepine or non-benzodiazepine hypnotic agents. 
Conclusions: Sleep problems and depression are common in kidney patients. Women are 
more prone to sleeping problems than their male counter-parts.  Furthermore, people who 
have low MCS scores are more prone to impaired sleep or vice versa.  
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Chapter 1: INTRODUCTION 
 
1.1 The Overview 
 
Chronic kidney disease (CKD) is a global public health problem that is expected to affect 
a great number of people in coming years.
1-3
 The condition is irreversible and related to 
shorter life expectancy.
2,8
 Infectious agents, drug-related causes, and glomerulonephritis 
are among the most common causes for CKD in developing countries, while diabetes 
mellitus and vascular/hypertension related disorders are responsible for causing the vast 
majority of cases in developed countries.
4-7
 Disease-specific treatment may be necessary 
in certain cases;
8
 management usually relies on preserving the current kidney function.
8,9
 
When kidney function is diminished by about 90%, one of the renal replacement therapies 
needs to be employed. This may include dialysis or a kidney transplant.
9
 
Sleeping problems and depression are more common in patients with kidney 
dysfunction.
10-17
 The gold standard for the diagnosis of depression is a patient-centered, 
structured interview,
11
 while sleep apnea requires polysomnography to make a definitive 
diagnosis.
12
 These clinical conditions have been associated with adverse health 
outcomes.
13
  Thus, it is important to diagnose and provide appropriate management in a 
timely manner.  
Although not a substitute for the gold standard, questionnaires—widely available and 
accessible tools—are used before more detailed exams or diagnostic procedures are 
employed. The Pittsburgh Sleep Quality Index (PSQI)
14
, Short Form 36 Quality of Life 
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Health Survey Questions (SF-36)
15
, and Beck Depression Index (BDI)
16
 were validated in 
CKD patients, and can be used for assessment of sleep quality, quality of life, and 
depression respectively. The Berlin Questionnaire (BQ)
17
 was also validated for sleep 
apnea screening. The aforementioned tools do not pose any risk in their application, and 
are easily applied. Therefore, their use has been reported in numerous studies world-wide. 
18,19,20,21,22
 
Screening tools are usually applied to high-risk populations for the associated condition, 
as mass screening may not be feasible. As a result, stratification of patients according to 
their risk status enables target screening, which decreases workload and unnecessary 
procedures. The determinants of sleep quality and depression in CKD patients have not 
been fully understood, although several predictors for both conditions have been well-
established in the general population.
23-28
 Identifying predictors for sleep quality are 
important since some of them may be modifiable, including blood glucose, blood 
pressure, obesity, and smoking.
29-30
 Moreover, sleep apnea and depression might share 
the same causal pathway with renal disease progression, such as sympathetic nervous 
system activation.
2
 Further, impaired sleep might lead to depression or vice versa.
31
 High 
prevalence rates and lack of knowledge regarding the correlates of the entities in kidney 
patients necessitate exploring the field further. We expected to identify factors strongly 
associated with poor sleep quality in patients with various stages of renal failure.  
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1.2 The Literature Review 
 
A literature review was performed. The searches were performed using the following 
databases (from inception to the week 3 of February 2013): MEDLINE (via PubMed), 
EMBASE, The Cochrane Library, and Web of Science. The following key words with 
various combinations were included in the search: “sleep quality,” “sleep apnea,” “sleep-
disordered breathing,” “depression,” “depressive disorder,” “quality of life,” “chronic 
kidney disease,” “dialysis,” “hemodialysis,” and “peritoneal dialysis”. The search covered 
prevalence, predictors, correlations, and management in both sleeping problems and 
depression in patients with CKD.  
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Chapter 2: BACKGROUND 
2.1 Definitions 
2.1.1 The Definition of Chronic Kidney Disease and its Epidemiology 
 
2.1.1.1 The Definition of Chronic Kidney Disease 
 
CKD is described as kidney damage caused by structural or functional abnormalities that 
persist for at least three months.
3
  One of the most widely used and accepted tools for 
defining CKD from a functional perspective is estimated glomerular filtration rate 
(eGFR).
3
 Different methods can be employed for this estimate, including the 
Modification of Diet in Renal Disease (MDRD) study equation
32
 and the CKD-EPI 
equation.
33
 An eGFR value of 90 ml/min/1.73 m
2
 or lower is considered CKD.
3,9
 
CKD can be also defined with normal eGFR levels if there are structural abnormalities 
such as kidney cysts or stones.
3
 Another  example would include the albumin: creatinine 
ratio (ACR) in a spot morning urine sample.
34
 This measurement is based on the 
comparison of the ratio of urine albumin to creatinine in mg/mmol, which provides a 
proxy for 24-hour albumin excretion.
34
 Urine ACR equal to or more than 3.5 mg/mmol 
for females and 2.5 mg/mmol for males signifies microalbuminuria and may indicate 
CKD, even in the presence of an eGFR > 90 ml/min/1.73 m
2
.
9
 
CKD can be divided into 5 stages according to eGFR (please see table 2.1 for the list of 
five stages of CKD).
9
 Stage 5 status may require dialysis treatment (stage 5D) or a kidney 
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transplant (stage 5T).
9
 However, some of the stage 5 CKD patients may be conservatively 
managed. 
Table 2.1: Stages of CKD according to eGFR
3
  
Stages of CKD eGFR, ml/min/1.73 m
2
 
Stage 1   ≥90  
Stage 2  60–89  
Stage 3  30–59  
Stage 4  15–29  
Stage 5  < 15  
Abbreviations: eGFR: estimated Glomerular Filtration Rate; CKD: Chronic Kidney Disease. 
Low GFR and the presence of persistent proteinuria have been independently associated 
with prognosis of CKD
9
 and lower survival rates.
35
 In this study, only eGFR was 
employed for defining reduced kidney function, due to the lack of ACR data.  
2.1.1.2 Epidemiology of Chronic Kidney Disease 
 
2.1.1.2.1 The Prevalence and Incidence of Chronic Kidney Disease 
 
CKD is a growing concern around the world, and according to a number of reports, the 
prevalence of the disease is increasing.
3
 Although the incidence and prevalence of CKD 
exhibit large variations between countries, approximately 8–16% of people are thought to 
be inflicted by CKD worldwide.
7
 North America is one of the regions in the world with a 
high number of cases with CKD. The prevalence of CKD among the adult population has 
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been indicated as over 10% in the United States (US), according to recent reports.
3,36
 
However, the rate of CKD, between 2005 and 2010, was 6.3% when defined by eGFR, 
and 9.2% when defined by ACR, according to the United States Renal Data System report 
in 2012.
37
 A 1.7% increase in the rates of CKD  between the periods of  1988—1994 and 
2005—2010 has been reported.37 According to recent data, a total of 25 million people 
have CKD and 500,000 need some kind of dialysis  therapy or a kidney transplant in the 
US.
38
  
Canada is another country with high prevalence rates of CKD. A total of 38,000 
Canadians had stage 5 CKD in 2009, according to the Canadian Organ Replacement 
Registry Report, and  59% (22,300) of stage 5 CKD patients were on dialysis treatment in 
the same year.
39
 The number of patients with stage 5 CKD reached 40,385, as reported by 
the Canadian Organ Replacement Registry Report in 2011. The incidence of stage 5 CKD 
in the same year was 5489 and 159.2 rate per million people.
40
 The prevalence rate for the 
same time period was 11,712 rate per million people in Canada.
40
 Newfoundland and 
Labrador is one of the provinces with a high degree of disease burden.
40
 In 2011, there 
were 141 incident cases of end-stage renal disease in the province, yielding an incident 
rate of 276.2 per million.
40
 
In addition to North America, other parts of the world have been inflicted with the CKD 
epidemic. The prevalence of age-standardized CKD in the adult population in England 
from stages 3 through 5 was indicated as approximately 8.5%.
41,42
 According to the 
United Kingdom Renal Registry Reports, a total of 41,776 adult patients with a 
prevalence of 694 per million population were on a renal replacement treatment in 2005.
43
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In 2008, the point prevalence was 756 rate per million people (a total of 58,287) for 
kidney failure while the incidence rate was 188 including pediatric patient population, 
according to the Turkish Registry Reports.
44
 
Prevalence rates change dramatically according to the definition of CKD, to the methods 
for collecting data, and to the characteristics of the study population. As a result, it might 
be difficult to compare the frequency of the disease from different jurisdictions without a 
standardized approach. In a large community-dwelling elderly cohort report by 
Hemmelgarn et al., the prevalence rate of CKD was 35.4%.
24 
In another report from the 
US, 7% prevalence was indicated using the Cockcroft-Gault formula.
45
  
2.1.1.2.2 Causes of Chronic Kidney Disease 
 
Renal registries fair better from an underlying diagnosis perspective as “the most possible 
cause for CKD” is one of the categories of the reports. These can thus serve as valuable 
data sources nationwide and enable comparisons between jurisdictions. The most 
common causes of CKD include glomerulonephritis, diabetes mellitus, renal vascular 
disease, polycystic kidney disease, drug-induced causes, pyelonephritis, and unknown 
causes.
40,46
 The most frequent cause of CKD in developed countries is diabetes mellitus, 
while infectious diseases, drug-related conditions, and glomerulonephritis are held 
responsible for the majority of cases in developing countries.
4-7
  Of all prevalent patients 
in Canada in 2011, the diagnosis most responsible for kidney failure was reported as 
diabetes mellitus (26%), followed by glomerulonephritis (22%) in the stage 5 CKD 
patient population.
40
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2.1.1.2.3 Risk Factors for Chronic Kidney Disease 
 
Hypertension, diabetes, and obesity are risk factors for CKD development.
7
 A total of 
approximately 1.5 billion adults around the world are expected to have hypertension by 
2025 .
47
  The prevalence of diabetes was 6.4% in 2010, and is expected to increase about 
1.3% by 2030 worldwide.
48
 Obesity has been associated with a higher risk for CKD 
development and/or progression, excluding the dialysis patient population.
49
 The number 
of overweight people has been increasing.
50
 As a result of the rise in the number of 
patients with hypertension, diabetes, and obesity, more people could be at risk for CKD 
development in the future. 
2.1.1.2.4 Survival and Associated Factors in Chronic Kidney Disease 
 
CKD has been correlated with increased mortality rates, and cardiovascular causes have 
been indicated as the leading cause of death.
51,52
 Age and primary diagnosis have been 
associated with prognosis in CKD patients.
40
 While age has been negatively correlated 
with survival, gender has not been indicated to be of significant influence on  survival.
40
 
Renal vascular disease and diabetes were shown to be related to the lowest five-year 
survival rates.
40
 
Comorbid conditions such as anemia, abnormal phosphate and uric acid levels, vitamin D 
deficiency, cardiovascular disease, congestive heart failure, and diabetes were also 
negatively correlated to survival in CKD patients.
52
 Anemia has been associated with 
increased cardiovascular disease and death in a large elderly study cohort.
53
  
Hyperphosphatemia has been correlated with progression of chronic kidney disease and 
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increased mortality.
54
 PD patients with high uric acid levels in a retrospective study 
indicated lower survival rates.
55
 It was suggested by Anand et al. that vitamin D 
deficiency might lead to increased mortality in dialysis patients.
56
 Similarly, it was 
indicated that oral vitamin D supplementation was associated with lower mortality in 
peritoneal dialysis (PD) patients.
57
 The presence of vascular disease has been associated 
with lower survival rates in CKD patients.
58
  
2.1.1.2.5 Costs Associated with Chronic Kidney Disease 
 
Although the health effects of CKD have been studied thoroughly, few studies analyzed 
the economic burden associated with the disease. It was shown that cumulative costs for 
inpatient visits, outpatient visits, and prescriptions were significantly higher in CKD 
patients, when compared to the non-CKD group in a large-scale case control design.
59
  
Total costs for treating dialysis patients have been rising. The cost has been reported as 
approximately $40 billion US  in 2009.
60
 The reimbursement for each hospital 
hemodialysis session in the US was reported as $689 US, while the amount was $745 US 
per session in Ontario, Canada.
61
 Reports also indicate that direct medical costs constitute 
70-80% of the total costs.
61
 A total of 30 hemodialysis patients were included in a 
prospective study with a six-month follow-up, and 76% of the total costs were attributed 
to direct medical and non-medical costs in India.
62
 Parallel to these findings, direct 
medical costs were reported as 81%, and the mean total cost per hemodialysis session was 
$297 US.
63
 Health expenditures in those with non-dialysis CKD as compared to the 
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dialysis population are less measurable. Strategies to improve allocation of limited health 
resources without compromising patients’ health and wellbeing require further research. 
2.1.1.2.6 Quality of Life in Chronic Kidney Disease 
 
Measurement of physical functioning is recommended, using SF-36 twice a year for 
dialysis patients.
64
 Quality of life was shown to be lower in dialysis patients when 
compared to the general population.
65
 It was also indicated that CKD contributes to poor 
quality of life and productivity losses.
54,59
 Regular assessment, encouragement for 
physical activity, and management of modifiable factors are recommended to increase 
physical and mental wellbeing of CKD patients.
59,64
 
2.1.1.2.7 The Management of Chronic Kidney Disease  
 
Since CKD affects all organ systems, the management of the condition requires a 
systematic approach and detailed considerations for preserving kidney functions and 
preventing extra-renal complications.
9
 Measurable care outcomes are considered to be 
cornerstones in CKD management, such as blood pressure, hemoglobin A1C, cholesterol, 
proteinuria, anemia, markers of bone and mineral metabolism, and dialysis adequacy for 
small solute clearance. However, these markers' association with patient-oriented 
outcomes is controversial.
7,9
 Emerging issues such as sleeping problems and depression 
have added new components to the standard care for kidney patients.
64
 Nevertheless, the 
most effective approach to prevent or even reverse progressive loss of kidney function is 
yet to be discovered. 
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A dialysis treatment or a kidney transplant needs to be started when patients reach the 
kidney failure stage. The vast majority of patients with kidney failure in the US prefer 
hemodialysis (HD).
66
 According to a recent report, the initial treatment of choice for 
dialysis treatment was HD in approximately 80% of patients in Canada.
40
 The most 
preferred choice as the initial dialysis treatment was HD in Newfoundland (93%), 
followed by New Brunswick (87%).
40
 PD, as the initial treatment of choice for dialysis, 
was about 16% Canada-wide.
40
 Newfoundland has the lowest provincial rate (7.2%) for 
incident PD patients.
40
 In only 4% of kidney failure patients Canada-wide, pre-emptive 
transplantation was the treatment of choice in the same year.
40
 
Arterial hypertension frequency in the CKD population has been shown to be high, with 
prevalence rates of 60%—82%.67-69 In addition to salt and water retention,70,71 increased 
sympathetic tone plays a major role in many cases and restoring the balance might be 
difficult.
72,73
 Adequate blood pressure control prevents several life-threatening 
complications and increases survival in CKD patients.
7
 It is worthwhile to test the 
association between blood pressure measurements and sleep quality, as imbalanced 
autonomic nervous system function promotes and provokes both conditions.  
The focus of this thesis is on problems that may be more commonly seen in CKD 
patients. Some of the relevant information about sleeping problems, depression, and 
quality of life in the general population is provided in the following chapters. The 
prevalence, risk factors, and health outcomes of these conditions in those with CKD will 
also be addressed.   
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2.1.2 The Definition of Disordered Sleep and its Epidemiology 
 
2.1.2.1 An Overview of Sleep 
 
Sleep has been an area of interest for many researchers. People spend approximately one 
third of their lifetime sleeping. Sleep is not a unified entity, but has different stages.
60 
Rechtschaffen and Kales first identified and scored sleep stages in 1967.
60
 According to 
this classification system, sleep consists of alternating rapid eye movement (REM) and 
non-rapid eye movement (NREM) stages, which further divides into four stages.
74,75
 
REM is composed of tonic REM, which is characterized by absence of muscle tone and 
eye movement, and phasic REM, which is characterized by muscle twitches and rapid eye 
movement.
76,77
 Please see appendix D for the diagram. 
According to the Rechtschaffen and Kales classification, an epoch is a basic unit in  
polysomnography and represents a stage of sleep.
75
 A scoring system is developed based 
on electroencephalogram (EEG), electro-oculogram (EOG), and chin electromyogram 
(EMG) tracings.
75
 Due to subjectivity associated with tracing interpretation, the 
evaluation system raised some concerns and required further improvement.
78
 
An updated scoring system was provided by the American Academy of Sleep Medicine in 
2007.
79
 According to this manual, sleep stages are defined as REM and NREM. NREM is 
divided itself into stages 1, 2, 3, and 4.
79
 Moser et al. tested the degree of agreement 
between the two sleep-classification systems.
78
 It was indicated that the percentage of 
total sleep time spent in stage 1, stage 2, and stage 3 was significantly different between 
the two classification systems.
78
 However, the total sleep time, sleep latency, and sleep 
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efficiency did not differ.
78
 Overall, the recent classification system decreased subjectivity 
in scoring, and as a result, it is preferred over the previous version. 
After the discovery of sleep stages, changes in the autonomic nervous system activity 
during different stages of sleep have also been studied. NREM sleep is associated with 
increased parasympathetic and decreased sympathetic activity.
80
 The outcome of this 
change is a drop in heart rate, blood pressure, and cardiac output.
80
 Nocturnal dipping is 
described as a 10%—20% drop of systolic blood pressure and requires normal vagal 
activity and cardiovascular relaxation.
81
 In many patients with kidney disease, due to an 
overactive sympathetic nervous system, nocturnal dipping is lost.
82
 Thus, those patients 
are called non-dippers and exhibit a blood pressure drop of less than 10% during 
sleep.
83,84
  
Further deterioration can be observed in reverse dippers, who have severely impaired 
autonomic function, with high blood pressure during sleep and eventually during 
wakefulness.
77
 As a result of changes in parasympathetic and sympathetic activity, an 
increase in blood pressure by 5% is also expected in REM sleep.
77
 Aside from the 
cardiovascular system, kidneys also experience some changes during sleep such as a 
decrease in GFR, renal blood flow, and the excretion of sodium and calcium; this is 
coupled with an increase in tubular water reabsorption and antidiuretic hormone (ADH) 
secretion.
77
 Plasma renin activity and aldosterone also fluctuate during different stages of 
sleep.
77
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Different classifications for sleep disorders are available, including the International 
Classification of Sleep Disorders (ICSD)
85
 and the Diagnostic Classification of Sleep and 
Arousal Disorders.
86
 The ICSD classification provides an axial system for sleep 
disorders.
85
 Axis A includes primary sleep diagnoses that are further divided into four 
categories: dyssomnia, including insomnia and excessive sleepiness; parasomnia; medical 
or psychiatric sleep disorders; and proposed sleep disorders.
85
  Axis B contains diagnostic 
tools including tests and procedures, such as all-night polysomnography and multiple 
sleep latency tests.
85
  Axis C lists medical or psychiatric disorders that are not primary 
sleep disturbances; recurrent depression and hypertension are classified under this 
category.
85
 According to the Diagnostic Classification of Sleep and Arousal Disorders 
classification system, sleep disturbances can be divided into four major categories: 
disorders of initiating and maintaining sleep , disorders of excessive somnolence, 
disorders of sleep-wake cycle, and parasomnias.
86
 Insomnia and sleep apnea are among 
the most common diseases that lead to poor sleep quality.
87
  
2.1.2.2 Insomnia 
 
The ICSD defines insomnia as “having difficulty in falling to sleep or maintaining sleep 
associated with severe daytime impairment”.88 The condition can be primary or secondary 
to pre-existing psychological diseases, especially mood and anxiety disorders.
88
 The 
duration, frequency, and severity of the disease can differ.
88
 According to the ICSD 
classification system, there are eleven types of insomnia including paradoxical,  
idiopathic, and adjustment insomnia.
88
 In selected cases, a sleep study can be ordered for 
a definitive diagnosis, although it is costly and cumbersome.
79
 There are several 
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questionnaires that indicate sleep quality, such as the PSQI.
14
 The measurement section 
includes detailed information related to measurement and assessment of sleep quality. 
The prevalence for chronic insomnia is about 10% in the general US population.
89,90
 
Female gender, low education, and low income are some of the risk factors for 
insomnia.
23,24
 Insomnia has been associated with lower quality of life and comorbid 
conditions, such as depression and anxiety disorders.
91,92
  
The association between sleep disturbances and shifted circadian rhythm of blood 
pressure has also been investigated. One hundred and thirty-three newly diagnosed 
hypertensive patients were included in the study, and sleep quality was assessed with the 
PSQI.
93
 An ambulatory blood pressure monitoring system was also employed.
93
 The 
PSQI global score was significantly elevated in non-dippers. Further, each component of 
the PSQI was also found to be elevated in non-dippers. As a result, it was concluded that 
the PSQI score was a predictor for non-dipping status (OR: 0.84, p < 0.004).
93
 Similarly, 
it was also shown that the PSQI global score was negatively correlated with night-time 
systolic and diastolic blood pressure readings (r: -0.46 and r: -0.42, respectively). Non-
dippers scored higher in the PSQI.
94
 
2.1.2.3 Sleep Apnea 
 
Sleep disordered breathing, also called sleep apnea, consists of a wide spectrum of 
diseases, from snoring to severe hypoxemia, that lead to consequent pathophysiological 
changes in different organ systems.
95
 The disease is characterized by transient cessation 
of breathing during sleep and can be with or without a compromised respiratory drive.
95
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Combination of sleep-disrupted breathing and excessive day-time sleepiness is called 
sleep apnea syndrome.
95
 
The terminology for sleep apnea facilitates clarity for diagnostic criteria and management, 
and some of the definitions are provided in the following pages. Hypopnea is described as 
a drop in airflow of at least 50% for at least 10 seconds and with a minimal oxygen 
desaturation of 3%.
95
 A drop in airflow of at least 90% for at least 10 seconds is 
considered apnea.
95
  The severity of the disease is defined by an apnea / hypopnea index, 
which is calculated by the total events per sleep divided by the total sleep time in hours.
95
  
Thus, the hourly rate of apnea and hypopnea is calculated. If the number of events is 
between 5 and 15 per hour, it is called mild; if the number exceeds 30 per hour, it is 
classified as severe sleep apnea.
95
  
According to the method for diagnosis, the prevalence of sleep apnea varies between 2% 
and 26 % in the general population.
25,29,96-99 
Young et al. studied the prevalence of sleep- 
related breathing disorders in the middle-aged population with a sleep study (n: 602). It  
was shown that the prevalence of sleep apnea was 2% in women and 4% in men.
29
  
Another population-based study in Spain indicated that 2.2% of men and 0.8% of women 
were diagnosed with sleep apnea, which was based on a questionnaire and nocturnal 
home oximetry.
97
 Parallel to these findings, in a large number of participants it was 
indicated that 1.9% of the respondents were diagnosed with sleep apnea.
98
 In another 
report, a questionnaire and home monitoring of respiratory disturbance index (RDI) were 
used for sleep apnea diagnosis. Of the 441 patients in this study, 17.9% of the participants 
met criteria for sleep apnea.
99
 26% prevalence was indicated when the Berlin 
 
 
17 
 
Questionnaire (BQ) was employed as the screening tool, and 57% of overweight 
participants were at high risk for sleep apnea.
96
 
 
Age, male gender, and obesity are the risk factors for developing sleep apnea in the 
general population.
29
 In addition, non-traditional risk factors, such as HbA1C, diabetes 
mellitus, smoking, depression, and anxiety have also been investigated for sleep apnea 
risk in the general population. Priou et al. studied 1599 non-diabetic patients to test the 
association between HbA1C and sleep apnea.
100
 Obstructive sleep apnea (OSA) severity 
and nocturnal hypoxemia were associated with HbA1C after adjustments were made for 
traditional risk factors, including age, sex, and body mass index (BMI).
100
 Patients with 
moderate and severe OSA had a higher chance of having HbA1C > 6% (OR: 1.8, 95% CI: 
1.19–2.72 for moderate OSA and OR: 2.02, 95% CI: 1.31–3.14 for severe OSA).100 It was 
also reported that diabetes mellitus has been associated with sleep apnea.
101,102
 
Furthermore, it was reported that current smokers were at risk for moderate sleep apnea, 
when compared to non-smokers (OR: 4.44).
30
 The study included a total of 811 adults, 
and a sleep study was performed for diagnosis.
30
 This finding was supported by a recent 
report that included 57 patients with sleep apnea.
103
  Duration of smoking was associated 
with the severity of sleep apnea and some structural uvular abnormalities in the tissue 
specimens.
103
 Depression was associated with a 2.5 times higher risk for sleep apnea in 
the general population.
102
 Lastly, a link between schizophrenia, anxiety, and OSA has 
also been suggested.
104
 
In regards to the negative health outcomes, sleep apnea has been associated with 
increased risk for stroke,
105
 hypertension,
106
 inadequate diabetes control,
107
 cardiovascular 
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events,
108,109
 and pulmonary hypertension.
110,111
 An overactive sympathetic tone in sleep 
apnea has been implicated for poorly controlled diabetes and hypertension.
111
 An 
increased cardiovascular event risk in sleep apnea has also been related to sympathetic 
activation and endothelial dysfunction.
13
  
OSA has been associated with cardiovascular mortality and morbidity in the general 
population. Marin et al. studied 1889 normotensive patients with and without OSA for 
hypertension development with a follow-up period of up to 17 years.
112
 Those with an 
OSA diagnosis were further classified as (continuous positive airway pressure) CPAP 
recommended and CPAP not recommended.
112
 Patients who did not adhere to CPAP 
treatment exhibited higher risk for developing hypertension (HR: 1.78, 95% CI: 1.23–
2.58) when compared to their adherent counterparts (HR: 0.71, 95% CI: 0.53–0.94), after 
adjustments were made for baseline covariates.
112
 It was concluded that CPAP treatment 
lowered the number of incident cases with hypertension.
112
 In line with these findings, 
another community-based study supports the evidence regarding the correlation between 
OSA and hypertension development.
99
  In a study cohort of 441 people, snorers and non-
snorers were compared in terms of hypertension and coronary artery disease.
99
 It was 
reported that patients with OSA had approximately a four times increased prevalence for 
high blood pressure (OR: 3.8, 95% CI: 1.9–7.5 for hypertension and OR: 3.5, 95% CI: 
1.2–10 for coronary artery disease) in unadjusted models.99 This finding was previously 
supported in three studies.
13,113,114
 
In addition to long-term negative health outcomes, sleep apnea has been linked to a 
higher likelihood of daytime sleepiness, which is a known risk factor for accidents.
98,115
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Patients with sleep apnea were tested with a computer-simulated road test and indicated 
higher likelihood for accidents as compared to control subjects.
116
 The fear of losing 
one’s driver’s license might pose a barrier to reporting the symptoms of sleep apnea. As a 
result, sleep apnea might be under-diagnosed. 
There have been several theories to explain the underlying mechanisms of sleep apnea 
(please see appendix B). First of all, autonomic system dysfunction is held responsible for 
the disease causation and severity. The exacerbated sympathetic tone and consequent 
activation of the renin angiotensin aldosterone system play a major role in the disease 
process.
117,118
 Structural abnormalities in the upper airway system are other 
considerations, and can be congenital or acquired.
119
 Acquired causes include obstruction 
of the airway as a result of excessive fat tissue or fluid. As a result, obesity and 
hypervolemic states such as congestive heart failure
120
 and CKD
121
 have been associated 
with the syndrome. An abnormal muscle function in the upper respiratory tract
119
 and 
possible fluid shift to the upper part of the body due to the recumbent position are 
considered other possible contributors.
122-124
 
Tailored interventions for the management of sleep apnea, depending on the clinical 
condition and patients' preferences, are possible. Underlying conditions, which may 
contribute to sleep apnea, such as hypothyroidism and acromegaly, should be considered 
and/or treated as the initial step.
125-127
 CPAP treatment, upper airway surgeries, and oral 
appliances are among different therapeutic choices
125
. Weight loss can be beneficial to 
those who are overweight.
125
 Supplemental oxygen and positional therapy (elevated head 
posture, supine posture, and specifically designed pillows) may be used in certain cases 
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without a proven survival benefit.
125
 Serotonin has mixed effects in terms of activating or 
inhibiting upper airway dilatator activity and central drive.
125,128
 Paroxetine and 
Fluoxetine are two of the selective serotonin reuptake inhibitors (SSRI) that have been 
shown to significantly decrease apnea hypopnea index.
128,129
 Moreover, REM sleep 
suppressant therapy includes SSRIs, such as Fluoxetine and Paroxetine, and tricyclic 
antidepressants, such as Protriptyline and Clonidine.
125
 This therapy can be administered 
to those with REM related OSA.
128
 Methylxanthines, including Aminophylline and 
Theophylline might also be beneficial in central sleep apnea.
130,131
 All in all, CPAP is the 
only treatment option that lowers the risk of mortality.
132,133
 It has been also indicated that 
CPAP treatment provides significant attenuation in daytime sympathetic activity.
134,135
 
2.1.3 The Definition of Depression and its Epidemiology 
2.1.3.1 An Overview of Depression 
The Diagnostic and Statistical Manual for Mental Disorders IV is a widely accepted 
classification system for mental disorders.
136
 It provides a classification system that 
employs five axes.
136
 Axis 1 includes clinical disorders, including major endogenous 
depression, while Axis 2 represents personality disorders.
136
 Axes 3, 4 and 5 encompass 
all physical, social, and environmental aspects and determinants for mental health.
136
  
Endogenous depression is included in Axis 1 with other major psychiatric disorders.  
The definition of depression is as follows:  
a clinical syndrome lasting at least two weeks, during which 
the patient experiences either depressed mood or anhedonia 
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plus at least five of the following symptoms: (1) depressed 
mood most of the day, nearly every day; (2) markedly 
diminished interest or pleasure in most activities most of the 
day; (3) significant weight loss or gain or appetite 
disturbance; (4) insomnia or hypersomnia; (5) psychomotor 
agitation or retardation; (6) inappropriate guilt; (7) 
diminished ability to think or concentrate, or indecisiveness; 
or (8) recurring thoughts of death, including suicidal 
ideation.
136
 
In the general population, the point prevalence of depression is 5-9% in women, and 2-
3% in men.
137
 Female gender, obesity, and socioeconomic status are risk factors for 
depressive disorder.
25-28
 Poor physical health has also been associated with increased risk 
for depression.
138
 In a large study cohort with different chronic diseases, it was reported 
that those with kidney failure and coronary artery disease were more prone to depression, 
when compared to those with rheumatic diseases, such as rheumatoid arthritis.
10
 The 
prevalence of depression was also shown to be higher in CKD patients as compared to the 
general population.
139
  
Recurrent depressive disorder has been associated with negative health outcomes 
including the development of hypertension, cardiovascular disease, stroke, diabetes 
mellitus, and lower survival rates.
140
 Depressive disorder has been associated with lower 
survival rates in those with diabetes, coronary heart disease and congestive heart 
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failure.
141-143
 Similarly, patients with kidney failure and depression were found to have 
lower survival rates.
144
 
Neurochemical imbalance in the central nervous system is the root of the problem in 
depressive disorder.
145
 The disease process involves several alterations in the brain and in 
the peripheral nervous system, including reduced serotonin and increased sympathetic 
tone.
145,146
 
The sympathetic nervous system is governed by the hypothalamic-pituitary-adrenal 
(HPA) axis. Corticotrophin Releasing Hormone (CRH) is one of the substances that is 
released by the HPA axis and stimulates the secretion of adrenocorticotropic hormone 
(ACTH).
147
 The ACTH stimulates the adrenal cortex and medulla, and increases 
Epinephrine and Norepinephrine levels.
147
 It was previously reported that CRH increased 
in depressive patients.
147
 The volume of space occupied by CRH neurons was 
significantly larger in patients with mood disorders.
148
  
The HPA is inhibited by Gamma Amino Butyric acid (GABA) and cortisol feedback. 
GABA is a neurotransmitter that exerts control over both depression and sleeping 
problems.
149
 An increased secretion has been observed with hypnotic medications, and 
reduced levels are evident in patients with depression and sleep disturbances.
150
 The 
principal synthetic enzymes for GABA are Glutamic acid decarboxylase (GAD) 65 and 
67.
149
 The density of GAD 65/67 was negatively correlated with the density of CRH 
neurons in a study that included post-mortem samples.
149
 In a review, it was also 
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indicated that plasma, cerebrospinal fluid and cortical levels of GABA were lower in 
patients with depression.
151
  
In addition to GABA, alpha 2 adrenoreceptors also have inhibitory effects on the HPA.
152
 
These receptors can be found in the central nervous system (CNS), and have been related 
to the central neurotransmitter receptor functions of Norepinephrine.
152
 Yohimbine acts as 
a receptor antagonist for alpha 2 adrenoreceptors and through this action has been linked 
to reduced Norepinephrine turnover.
152
 A reduced alpha 2 adrenoreceptor function might 
cause increased central sympathetic tone, as a result of increased Norepinephrine 
production.
152
 
Norepinephrine is one of the neurotransmitters of the sympathetic nervous system and has 
also been implicated in the pathogenesis of depression.
146
 High total serum levels of 
Norepinephrine have been found in patients with depressive disorder.
146
 Similarly, Veith 
et al. studied Norepinephrine kinetics in depression and indicated high plasma 
Norepinephrine levels were present.
153
  High plasma Norepinephrine levels and high 
neuronal uptake of Norepinephrine in the CNS were also found by previous studies.
154
  
Overall, the underlying pathophysiology of major depression is complex, and involves 
several substances.
152
 Due to a lack of the negative feedback of GABA and/or alpha 2 
adrenergic systems, the HPA becomes overactive with elevated CRH levels.
152
 CRH 
stimulates corticotrophs, and ACTH is secreted. As a result, a sympathovagal imbalance 
is established, contributing to the disease process.
120,121
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Pharmacotherapy, psychotherapy, and electroconvulsive therapy are the cornerstones of 
major depression treatment.
137
  Tricyclic antidepressants; monoamine oxidase inhibitors; 
SSRI; serotonin and noradrenaline reuptake inhibitors; and selective norepinephrine 
reuptake inhibitors are the main groups of medications.
155-157
 SSRIs are considered as the 
first-line agents in the vast majority of cases due to their reasonable safety profile.
157
 
Ketamine is a glutamatergic N-methyl-D-aspartate receptor antagonist and a newly 
emerging therapeutic choice for depressive disorder.
155
 
2.2 Measurements 
2.2.1 The Gold Standard and Surrogates for Measuring Sleep Disturbances 
There are several tools to diagnose sleep disturbances. A complete history-taking and a 
thorough physical exam should be the initial step.
12
 Questionnaires can be employed to 
measure day time sleepiness and risk for sleep apnea.
17
 Subjective information about the 
patient’s sleep pattern can also be obtained by sleep logs.158 Actigraphy is a tool used to 
assess sleep latency, sleep efficiency, total sleep time, and the number of awakenings 
during sleep.
159,160
 Computed tomography and magnetic resonance imaging are among 
diagnostic modalities that are used to visualize the upper respiratory system.
160
 
Polysomnography, portable or in-center, is the gold standard for diagnosing many sleep 
disorders.
12,161
 
2.2.1.1. The Gold Standard for Diagnosing Sleep Disturbances 
 
The recommended objective testing method to establish a definitive diagnosis for sleep 
disturbances is a center-based polysomnography or home testing with portable monitors, 
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as previously mentioned.
12,162
 EEG, chin EMG, and EOG are recorded during the sleep 
study.
79
 Each sleep epoch is scored individually, according to the recordings from EEG, 
EMG, and EOG.
79
 As a result, all stages of sleep are described.
163
 Apnea hypopnea index 
and RDI are recorded throughout sleep.
79
 The diagnosis of sleep apnea is made when the 
number of obstructive events, including apnea and hypopnea, exceeds 15 events per 
hour.
79
 
Although the gold standard for the diagnosis of sleep apnea is polysomnography,
12,162
 this 
method is cumbersome and costly. A few questionnaires, such as the PSQI
14
 and BQ
17
, 
are used to screen sleeping problems and to select cases for further evaluation. The 
PSQI
14
 includes questions about falling to sleep and maintaining sleep
14
 while the BQ
17
  
focuses more on sleep apnea.   
2.2.1.2 Surrogates for Measuring Sleep Disturbances 
 
Self-reported questionnaires are commonly used to evaluate various aspects of sleep 
conditions in the adult population. The Insomnia Severity Index (ISI),
164
 Sleep Disorders 
Questionnaire,
165
 Athens Insomnia Scale Instrument,
166
 Post-Sleep Questionnaire,
167
 and 
PSQI are briefly described and discussed in this paper, although there are many other 
instruments. Those questionnaires, which are validated with established reliability, 
simple, and well-accepted, are preferred in different health care settings. 
The ISI questions problems about sleeping in the last two weeks.
164
 ISI is assessed based 
on a global score with an emphasis on loss of day-time functioning, rather than severity of 
insomnia.
168
 Sleep onset latency, sleep duration, and sleep medication use are not covered 
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in the ISI.
168
 The tool indicated a high internal consistency value in menopausal women 
(the Cronbach's alpha: 0.87).
169
 The PSQI and ISI were tested for accuracy and the area 
under the receiver operator characteristic curve was 0.79 and 0.78 for the PSQI and ISI, 
respectively.
168
 The values between 0.8 and 0.9 indicates good diagnostic accuracy, while 
0.9 and above is considered excellent for diagnostic accuracy.
170
 As a result, the PSQI 
and ISI have a good diagnostic accuracy.  
The Sleep Disorders Questionnaire has 175 domains, with categories for sleep apnea, 
narcolepsy, periodic limb movements, and psychiatric sleep disorders.
165
 The test 
underwent validation against clinical evaluation and polysomnography, and indicated 
considerable test-retest reliability (Spearman rho for sleep apnea: 0.84).
165
 However, the 
tool does not indicate sleep quality. 
The Athens Insomnia Scale Instrument questions about problems falling to sleep during 
the past month.
166
 The tool was indicated a considerable internal consistency and test-
retest reliability (the Cronbach's alpha: 0.9 and the correlation coefficient: 0.9) in the 
general population.
166
 A cut-off of 6 indicated 93% sensitivity and 85% specificity in a 
large study cohort.
171
  The tool has not been validated in the CKD population. 
2.2.1.3 The Pittsburgh Sleep Quality Index   
 
The PSQI is an instrument used to screen sleep quality and disturbances during the 
previous month.
14
 The questionnaire poses a total of 18 questions with a score range of 0 
to 21.  The tool has seven domains: subjective sleep quality, sleep latency, sleep duration, 
habitual sleep efficiency, sleep disturbances, use of sleep medication, and daytime 
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dysfunction over the last month.
14
 A sum of the seven component scores produces a 
global score. Buysee et al. studied 148 patients to validate the PSQI against 
polysomnography.
14
 The report showed that the domains of the PSQI was internally 
consistent and valid after an 18-month period of field testing.
14
 Furthermore, a global 
score higher than five was associated with 89.6% sensitivity, and 86.5% specificity in 
defining sleep quality, when compared to polysomnography.
14
 The tool indicated test-
retest reliability, and internal consistency was high (Cronbach's alpha: 0.83).
14,172
 
The PSQI has several advantages over other assessment tools for sleep quality. Firstly, 
the instrument questions the intermediate time frame between post-sleep inventories, 
questioning the previous night’s sleep and survey-type questionnaires, which in turn 
question the previous year. The post-sleep inventory and post-sleep questionnaire 
evaluate a subject’s previous night’s sleep.167,173 A sleep diary questions about the past 
week, whereas the ISI questions about sleeping problems in the last two weeks.
164
 
Survey-type questionnaires evaluate a one-year timeframe, which might pose a risk for 
recall bias. 
A global score also enables the comparison between subjects and within subjects.
14
 
Lastly, seven components of the PSQI screen possible sleep-related issues throughout the 
day and night.
14
 The PSQI was also shown to be applicable to different patient 
populations, such as the elderly,
174
 those with panic disorder,
175
 those with AIDS
176
, and 
those with CKD.
177
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2.2.1.4 The Berlin Questionnaire  
 
As previously mentioned, polysomnography is considered the gold standard for the 
diagnosis of sleep apnea, but in itself it is somewhat cumbersome and costly to screen for 
the disorder in those at risk. The BQ is a self-administered instrument used to screen for 
sleep apnea.
17
 The questionnaire has ten questions and three components.
17
 The first 
component has five items that indicate the presence and frequency of snoring in addition 
to witnessed apnea during sleep.
17
 The second component is associated with wake-time 
sleepiness and fatigue.
17
 Finally, the last component includes high blood pressure and 
obesity, defined as a BMI > 30Kg/m². In components one and two, a total score of at least 
2 is required to be qualified as a positive result.
17
 On the other hand, category three is 
considered positive in the presence of either a diagnosis of hypertension or obesity.
17
   If 
only one component of the three is positive, this indicates a low risk for sleep apnea.
17
 If 
two or more components are positive, this indicates a high risk for sleep apnea.
17
 Thus, 
the outcome of the tool is classified as high risk or low risk. 
Netzer et al.  tested the validity of the BQ in identifying high risk patients for sleep apnea 
in primary care settings.
17
  In this study, the gold standard was the RDI assessed by 
portable monitoring during sleep.
17
 An oxygen desaturation index was also assessed.
17
  Of 
the 744 participants, a total of 279 (37.5%) were identified as at high risk for sleep apnea 
by the BQ.
17
 One hundred had polysomnography with the portable monitor: 69 high-risk 
and 31 low-risk patients. A positive response in category one was associated with the 
highest post-test probability (78%) for a respiratory disturbance event, while a positive 
result in category two was associated with the lowest post-test probability (63%).
17
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Overall, the psychometric performance of the BQ against the RDI was as follows: 
sensitivity 86%, specificity 77%.
17
 The major weakness about this study is that not all 
participants underwent polysomnography, which might pose a risk for a selection bias. 
The Greek version of the BQ was also validated against polysomnography in the primary 
care setting with a sensitivity of 76% and a specificity of 40%.
21
 In another study by 
Amra et al., the sensitivity and specificity were reported 84% and 61.5%, respectively.
22
 
To our knowledge, the BQ has not been validated in CKD patients. 
2.2.2 The Gold Standard and Surrogates for Measuring Depression 
 
2.2.2.1 The Gold Standard for Measuring Depression 
 
The gold standard for diagnosing depressive disorders is the structured clinical interview, 
according to the diagnostic criteria stated in  the National Institute of Health and Clinical 
Excellence guidelines.
11
 The  Hamilton Depression Rating Scale
178
 is one such interview-
based diagnostic tools and can be administered by appropriately trained health 
professionals. The Hamilton Depression Rating Scale was used for depression screening 
in dialysis patients and indicated 35%–38% of patients had depression.179,180 
Although the structured clinical interview is the gold standard for diagnosis, several 
validated questionnaires may be used for screening purposes. The KDOQI guidelines 
recommended several psychometric testing instruments for depression and anxiety 
screening in dialysis patients.
64
 The Beck Depression Inventory (BDI)
3
,
 
Beck Depression 
Inventory Short Form Medical Patients (BDI-FS)
181
, and Cognitive Depression Index 
(CDI)
182
 are recommended by the guideline as  tools for depression screening in dialysis 
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patients.
64
  The BDI is one of the widely applicable self-report instruments for evaluation 
of depression both in the general population and among CKD patients. The BDI-FS
181
 is a 
short form of the BDI and serves  the same purpose. The CDI was produced from the BDI 
by omitting six somatic complaints of depression.
183
 The tool was tested in dialysis 
patients, and results indicated that sensitivity and specificity associated with the tool was 
similar to the BDI.
183
 Thus, it was indicated that the CDI was not superior to the BDI.
183
 
Moreover, the guideline indicated that the CDI might overestimate depression rates in the 
dialysis population.
69
 The BDI was validated in CKD patients as a recommended tool for 
depression screening;
64
 therefore, it was employed in this study. 
2.2.2.2 Surrogates for Measuring Depression 
2.2.2.3 The Beck Depression Inventory  
The BDI is used to measure severity of depression.
16,184
 The BDI was developed based on 
attitudes and symptoms of depressed patients that were represented in 21 categories. The 
tool was validated against the structured clinical interview with a high degree of 
reliability and validity in the general population.
184
 Later on, the instrument was also 
validated for the dialysis population with a score cut-off of 16.
185,186
 A total of 62 dialysis 
patients were studied to validate the inventory, which was shown to have 91% sensitivity 
and 86% specificity by Watnick and others.
185
   
The standard version of the BDI has 21 questions, and each question is scored on a 4- 
point scale (0-3). The total score range lies between 0 and 63, and higher scores are 
consistent with more severe depression. The BDI-FS
181
 has 7 components, and the total 
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score ranges from 0 to 21.  In the dialysis patient population, the tool was validated 
against BDI with a threshold of 16 and 4 in the BDI and BDI-FS, respectively.
187
 
It has been recommended by the KDOQI guidelines that dialysis patients be screened for 
depression and anxiety at dialysis initiation and every six months hereafter.
64
  Earlier 
stages of CKD might also require an evaluation for depression as a part of standard care; 
however, routine screening for depression in those with stages 1 through 4 CKD patients 
has not been recommended by the KDOQI guidelines.
188
 Nevertheless, the effectiveness 
of regular screening for depression has not been well proven, since there are no studies 
indicating better patient-oriented outcomes associated with regular screening. 
2.2.3 Methods for Measuring Quality of Life 
 
Quality of life may be measured by questionnaires, and there is no gold standard for the 
measurement.  The Short Form 36 Quality of Life Health Survey Questions (SF-36),
15
 
Kidney Disease Quality of Life Short Form (KDOQL-SF), and Euro-QoL-5 Dimension 
(EQ5D) are commonly used questionnaires. The EQ5D has five components, which cover 
mobility, self-care, usual activities, pain, and depression.
189
  The tool is not commonly 
used in CKD patients. SF-36 has generic and disease specific forms, and has been 
validated for dialysis patients.
190
 The disease specific form is called the Kidney Disease 
Quality of Life Short Form (KDOQL-SF).
191
 It encompasses the general scale version 
1.0, and the disease specific scale items based largely on symptoms that might be 
experienced by CKD patients. The drawbacks of the version 1.0, described in the 
following pages, might apply to the KDOQL-SF.  Moreover, the time required to 
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complete the KDOQL-SF questionnaire makes implementation cumbersome and 
impractical.  
We used the SF-36 version 2.0 in this study, and the tool has been validated for CKD 
patients, which only included the dialysis patient population.
180
 Physical functioning was 
assessed by an accelerometer in the validation of the SF-36.
190,192
  We decided to use the 
tool in our study because of ease of use, widespread use in chronic disease populations, 
and availability of norm-based comparisons. 
 
The SF-36 (Medical Outcomes Trust, Boston, MA) contains 36 questions and can be used 
for comparing populations, screening patients, and comparing the health benefits of 
different treatment options.
15
 The tool exists in a developmental form (1988), a standard 
form version 1.0 (1990), and a standard form version 2.0 (1998).
193
 Both standard forms 
have versions based on four-week recall and based on one-week recall.
194
 
The SF-36 version 2.0, also called the international version, was developed to increase 
reliability and validity of the instrument. It has the same number of questions as version 1 
and is considered superior due to the improvement in the layout and delivery of the 
questionnaire, which includes instructions, item wording, and response categories. The 
questions and responses are formatted horizontally in version 2.0 while the previous 
version had a mixture of horizontal and vertical formats, which reduces the clarity of the 
meaning, especially for elderly respondents.
193
   
In addition to improvements in the layout of the previous version of the instrument, 
several modifications were also implemented in the delivery of the questionnaire.
193,194
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Larger type size and bolding of instructions are among these changes.
193,194
 Moreover, 
several wording changes to clarify understanding were also made in version 2.0.
193,194
 
One of the examples of these changes in item wording took place in question three, which 
measures physical activity.
193,194
 The term “one block” was replaced with one hundred 
yards, and the term “several blocks” was replaced with several hundred yards.193,194  
In the later version, two changes occurred in the response categories: replacement of 
dichotomous response with five-level response in the role physical and role emotional 
scales and replacement of six-level response with five-level response in the mental health, 
and vitality scales.
193
 Firstly, the response choice for the role functioning scale, which 
included role physical and role emotional, was initially a binary variable.
193
 A five-level 
categorical rating scale was adopted for the frequency of role limitation in the newer 
version.
193
 This change was associated with increased score precision and reliability.
193
  
Secondly, limitations in vitality and mental health were included in question nine, and the 
six- response choice was reduced to five to simplify the format.
193
  
The SF-36 form has 36 questions, eight scales, and two summary measures. The eight 
scales are as follows: physical functioning (PF), role physical (RP), bodily pain (BP), 
general health (GH), vitality (VT), social functioning (SF), role emotional (RE), and 
mental health (MH). PF, RP, and BP contribute to the physical component summary 
(PCS), whereas MH, RE, and SF contribute to the mental component summary (MCS). 
VT, GH, and SF contribute to both summary measures.
193,194
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In both versions of the SF-36, it is possible to perform the original standard 0–100 scoring 
and norm-based scoring. The norm-based scoring employs a linear transformation of the 
scores from the original scoring system to generate a mean of 50 and SD of 10 in the 
general US population. Normative data for the SF-36 were also published for the 
Canadian population.
195
 Thus, the same mean and SD are applied to all scales, which 
simplifies the interpretation of the scores and enables comparison of scales, summary 
measures, and the two versions.
193
  
Since the average score and SD for the calculation of each scale is different, the 
interpretation may be difficult in the standard scoring system.
194
 In norm-based scoring, 
on the other hand, a constant mean and SD are applied to all scales.
194
 A score higher than 
50 is deemed above the general population norm, while a score of less than 50 is 
considered below the general population norm.
194
 Overall, the major effects of the 
disease, in terms of the impact on the components of quality of life, are reflected in the 
profile of scores across the scales.
194
  
Further, the norm-based scoring enables comparison of the components and the two 
versions of the tool by reducing ceiling and floor effects.
194
 The SF-36 encompasses 
questions with wide and narrow score ranges.
194
 The former yields a high ceiling whereas 
the latter sets the ceiling low.
194
  As a result, the scales introduce peaks and valleys, 
which reflect both the actual difference in disease effect and arbitrary differences between 
ceilings and floors due to the differences in the response range.
194
 The norm-based 
scoring system eliminates the random difference in ceiling and floor values that is 
unrelated to health outcomes.
194
 As a result, unbiased representation of peaks and valleys 
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enables comparison of scales, summary measures, and versions 1.0 and 2.0. This is not 
possible in the standard scoring system.
194
 Because of these reported advantages, norm-
based scores were employed in the analysis of this study.
193
 
The scoring of the instrument employs several steps.
194
 Each response choice is assigned 
a precoded value.
194
 The processing of the questionnaire starts with the data entry of 
precoded values into the system followed by an evaluation for missing and out of range 
values.
194
 Scale scoring is the next step for producing a final value for each scale. BP, HT, 
and some items of GH, VT, SF, RE, and MH are reverse-scored and recoded to compute a 
final item value for each component of the scales.
194
 The rest of the items retain the 
original precoded value.
194
 A sum of final values for each item within each of the scales 
gives the raw score for each scale.
194
 Thus, all items in each scale are summed to obtain 
raw scale scores. Consequently, raw scale scores are transformed to a 0–100 scale  called 
the transformed scale score.
194
  
Finally, norm-based scale scores are produced by a second transformation to a mean of 50 
and SD of 10 in the general US population after z-score standardization is applied to the 
scales. Computation of the physical and mental components is the last step for the scoring 
of the instrument. High scores indicate better physical functioning, general health, 
vitality, social functioning, role emotional functioning, and mental health, while higher 
pain scores indicate a lack of pain.
193,194
 
Step 1: Transformation:
194
 Transformation to a 0–100 scale:194 Transformed scale= 
[(Actual raw score-lowest possible raw score)] / [Possible raw score range] * 100. 
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Step 2: Standardization:
194
 Formulas for z-score standardization of SF-36v2 scales 
employ means and SDs from the 1998 general US population. The difference between the 
raw scale score and the mean is divided by SD to obtain z-score standardization.
194
  
Step 3: Transformation:
194
 Norm-based transformation of each scale of SF-36v2 z-scores 
is computed as follows: z-score of each scale is multiplied by ten and then the total value 
is added to 50.
194
  
Step 4: Aggregation of scale scores to compute the physical and mental health 
components:
194
 A prespecified coefficient value is multiplied by each standardized scale 
score and the resulting products are then summed across all the scales that contribute to  
PCS and MCS scores, whichever is being computed. 
Step 5: T-score transformation of component scores:
194
 Aggregate physical and mental 
component scores are multiplied by ten and added to 50 to produce transformed 
component scores (PCS and MCS).
194
  
The software for the scoring of the tool (QualityMetric Health Outcomes 
TM
 Scoring 
Software 4.5) was recently developed, and a comma-separated-values (CSV) format of 
the excel sheet can be uploaded into the instrument.
196
 The scores, both standard and 
norm- based, are provided instantly. The software is designed to eliminate bias due to 
missing data. It is also convenient and reduces the chance of incorrect calculations. 
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2.3 The Rationale for the Study 
2.3.1 Existing Literature in the Area of Chronic Kidney Disease and Dialysis 
2.3.1.1. Sleep Disturbances 
Sleep disorders are much more common in patients with CKD, and the prevalence rate 
was shown to be 44% in a systematic review.
197
 This was consistent with other studies 
that reported 50% prevalence in dialysis patients.
198-202
  Restless leg syndrome, sleep 
apnea, sleep disruption, metabolic changes due to kidney failure, medications, poor sleep 
hygiene, and depression were indicated as underlying reasons for this high frequency of 
sleep disorders.
199-202
  It was shown that sleep quality improved after dialysis dose was 
increased in PD patients.
203
 Overall, hypnotic use for sleep disturbances was reported 
26% to be in CKD patients.
204
 
There are conflicting reports regarding the association of sleep quality, quality of life, and 
survival in dialysis patients. Insomnia was associated with lower quality of life in addition 
to lower survival rates, according to several reports.
199-202
 In contrast, poor sleep was not 
correlated with an increased risk of death, according to a study that included 128 HD 
patients.
205
 Parker et al. studied 46 HD patients for sleep quality and quality of life. In 
accordance with the previous study, quality of life scores were not associated with 
polysomnography measurements.
206,207
  As a result, there are several studies for, and few 
studies against, the hypothesis regarding the correlation between sleep quality, longevity 
and life quality in patients on dialysis. 
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Sleep architecture is also affected as a result of neurohormonal changes in CKD, 
according to several reports.
198
 Jurado-Gamez et al. studied the architecture of sleep in 32 
HD patients,  and 19 healthy controls with a sleep study.
198
 REM and sleep efficiency 
were shown to be lower,
206,198
  while sleep latency and stage 1 NREM sleep were longer 
in the dialysis group.
198
 Longer stage 1 and stage 2 NREM sleep, and lower sleep efficacy 
were also reported in dialysis patients.
208
 The evidence suggests that sleep structure is 
affected in CKD patients.  
Another area of interest for many researchers is correlates of poor sleep quality in dialysis 
patients. According to a study report, gender, marital status, hemoglobin, and albumin 
were not associated with poor sleep, while young age was.
205
 In contrast, age and 
smoking have been associated with an increased risk for poor sleep quality.
209
 
Malnutrition and high calcium phosphate product have been linked to impaired sleep in 
PD patients.
177
 Cengic et al. underscored the link between high phosphate and high PTH 
levels with sleeping problems in HD patients.
210
 Depression was reported as one of the 
predictors for impaired sleep in a CKD study cohort.
211
 Additionally, dialysis shift in the 
morning was also correlated with impaired sleep, according to the report from a large 
study cohort.
209
 Dialysate temperature was also tested as a modifier for poor sleep quality. 
It was suggested that HD with cool dialysate could improve sleep by decreasing 
sympathetic activity.
212
 
Sleep apnea is a condition that contributes to poor sleep, and is common among CKD 
patients. Sleep apnea was indicated as one of the most prevalent sleep disorders among 
that population.
197
 Kimmel et al. studied 26 hemodialysis patients and performed 
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polysomnography that indicated 73% of patients had sleep apnea.
213
 These findings were 
similar to other studies that included HD patients, and supported higher prevalence 
rates.
198,214
  Additionally, HD patients have an approximately four-fold increased risk for 
severe sleep apnea, when compared to the age, gender, and BMI matched control 
group.
215
 
Correlates of sleep apnea have been studied in CKD patients. Obesity has been associated 
with a high risk for sleep apnea in dialysis patients.
216,217
 Central obesity was also 
suggested as a predisposing factor in kidney patients.
218
 According to a recent report, PD 
patients indicated a higher prevalence of sleep apnea than HD patients.
219
 In contrast, 
dialysis modality was not associated with the prevalence and severity of sleep apnea in 
dialysis patients.
220
 Clinical consequences of sleep apnea include increased risk for 
cardiovascular complications,
108,109
 systematic and pulmonary hypertension
106,110,111
, and 
lower survival rates.
112
 
Different from the general population, central and mixed sleep apneas are more common 
in kidney patients. Of 11 dialysis patients, 7 had mixed (central and obstructive) sleep 
apnea, according to a report from Miskowiec et al.
78
 Other reports also supported the high 
prevalence of central sleep apnea among HD patients.
198,208
 The uremic toxins are held 
responsible for the high proportion of central sleep-disturbed breathing disorder in CKD 
patients.
198,208
 
In addition to higher prevalence rates and our lack of knowledge about predictors of sleep 
apnea in kidney patients, the disease can be under-diagnosed as patients can fail to exhibit 
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the usual symptoms of the disease.
43
 Beecroft et al. studied 76 dialysis patients to 
examine the difference in clinical presentations between the groups in a case-control 
design (n: 380).
43
 A sleep study and Epworth Sleepiness Scale were employed in the 
study.
43
 Snoring, witnessed apnea during sleep, and daytime sleepiness were less frequent 
in dialysis patients.
43
 This study indicated that sleep apnea might be under-diagnosed due 
to atypical presentation. Additionally, it was shown that dialysis patients with sleep apnea 
had a lower BMI than the control group, which consisted of sleep apnea patients with 
normal kidney functions.
43
 
Overall, CKD patients are prone to sleep disturbances that result in poor sleep quality.
197
  
Inadequate sleep is the root of the problem that ranges from accidents to long-term health 
effects including hypertension, as well as lower quality of life and life expectancy.
92,112,107
 
Sleep apnea is one of the most common causes for sleep disorders, and can be left 
unrecognized due to atypical presentation in kidney patients.
43
 Although the determinants 
of the disease are well-defined in the general population, a lack of evidence supporting 
the correlates in CKD patients necessitates further investigations in that area. 
Furthermore, most of the data are from the dialysis population, and identifiers of poor 
sleep quality in non-dialysis CKD patients also requires more research. 
2.3.1.2. Depression 
 
The prevalence of depression is reportedly higher in patients with kidney failure, and has 
been studied previously. Balogun et al. studied  approximately 600,000 non-dialysis CKD 
patients with a five-year follow-up period.
221
 The overall prevalence of depression was 
 
 
41 
 
indicated as 30%, which was considerably higher than the normal population.
221
  The 
diagnosis of depression was based on the structured clinical interview and/or reported 
antidepressant medication use.
221
 Su et al. studied 320 HD patients and employed BDI for 
depression screening.
18
  The prevalence of depression was 23.9% in those who received 
conventional HD.
18
 Cilan et al. studied 40 PD patients, and found that 25% of patients 
were depressive, when BDI was employed as a screening tool.
19
 These results were in line 
with other studies related to depression  in dialysis patients.
20
 Saeed et al. screened 180 
HD patients for depressive disorder using BDI with a high prevalence rate (75%).
222
 
Similarly, the prevalence of depression was 61.4%  in HD patients with a 16 cut-off in 
BDI.
223
 BDI provided only 4% false-positive cases in a group of HD patients, and the 
actual rate of depression was 26%.
224
 
In addition to the higher prevalence rates, the health outcomes of depression in kidney 
patients were also studied. Peritonitis rates were higher in those with depression in a 
study cohort.
225
 This was confirmed by a previous report.
226
 Depression might also affect 
quality and longevity of life in CKD patients.
180
 Feng et al. studied 362 adult CKD 
patients. The prevalence of depression was 13%, and correlated with a lower quality of 
life.
227
 However, those with depression did not indicate lower survival rates in a four year 
follow-up period (OR: 2.62, 95% CI: 0.77–8.89, P: 0.13) after adjusted analysis.227  
Contrary to these findings, Tsai et al. included 428 non-dialysis CKD patients to examine 
the association of depression with survival. A total of 37% of patients had depressive 
symptoms with the BDI. In unadjusted models, the hazard ratio for death was 2.63 (95% 
CI: 0.99–6.91) in depressive patients.228 Depression could be associated with the 
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comorbidities that lead to death, since diabetes, history of depression, and other 
psychiatric illness were significantly higher in the depression group as compared to the 
non-depressive group. These findings were in line with other studies that examined the 
relationship between depression and mortality.
221,229
 After adjustments were made for 
comorbidities, mortality was significantly higher in those with depression, according to a 
recent report that included a large CKD study cohort.
221
 It was also reported in the same 
report that age-adjusted survival rates were significantly lower in those with depression 
(hazard ratio: 1.55, 95% CI: 1.54–1.57,  P < 0.001).221  
Correlates of depression such as age, comorbid conditions, seasonality, eGFR, and renal 
disease progression were also examined in few studies in CKD patients. An association 
between young age and comorbid conditions with depression was indicated.
221
 Patients 
with depression indicated a higher incidence of diabetes and coronary artery disease when 
compared to those without depression in a study cohort that included 162 PD patients.
225
  
The seasonality of depression was also studied in patients with kidney failure.
230
 A total 
of 66 kidney failure patients were included, and BDI was performed in June and January 
to test seasonal fluctuations in mood.
230
 PCS and BDI scores were significantly lower in 
June.
230
 Depression and eGFR were not correlated, according to the findings from Feng et 
al., whereas eGFR was linked to an increased risk for depression in a large study 
cohort.
227,231
 Depression was indicated as an independent risk for renal disease 
progression and death in a report by Tsai and others.
228
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There are controversies around the safety and efficacy of the antidepressant medications 
in CKD patients.
232
 Nagler et al. performed a systematic review that included a total of 28 
studies to test the efficacy and safety of antidepressant treatment in stage 3-5 CKD 
patients.
232
  Except for three studies, sample size was lower than 20.
232
 It was indicated 
that the elimination half-life was increased while clearance was decreased for some of the 
antidepressant medications.
232
 It was also suggested that pharmacokinetic changes might 
be significantly different in kidney patients, and treatment did not show any significant 
clinical effect with antidepressant, when compared to a placebo.
232
 The lag time for 
clinical improvement was 3-6 weeks in the general population while in CKD it could be 
up to 12 weeks.
232
 
Due to different pharmacokinetics and increased lag time for clinical improvement, 
antidepressants should be administered with extreme caution in CKD patients.
232
 The 
Chronic Kidney Disease Antidepressant Sertraline Trial  is a randomized double blinded 
placebo controlled trial for safety of Sertraline treatment in stage 3-5 CKD patients with 
depression.
233
 The study has not been completed yet, but it is expected to add valuable 
information in regards to management of depression in kidney patients. 
2.3.1.3. Quality of Life 
 
Quality of life has been reportedly low in patients with CKD
234
, and various determinants 
of quality of life in CKD patients have been previously studied including anemia, stages 
of CKD, and dialysis modalities.
235-238
 Firstly, early and complete correction of anemia 
has been associated with better life quality indexes.
235,239
 The Cardiovascular Risk 
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Reduction by Early Anaemia Treatment with Epoetin Beta study indicated early treatment 
of anemia was correlated with a significant effect.
235
 A multicentre study included 596 
hemodialysis patients, who had no symptomatic cardiac disease, in a randomized 
controlled trial. Complete correction of anaemia was associated with higher energy 
scores.
239
 
Further, the stage of CKD has been associated with quality of life scales. SF-36 was 
employed in a cohort of 634 CKD patients.
236
 Based on the historical data, comparison 
was made between the CKD group, HD patients, and healthy control.
236
 CKD patients 
exhibited significantly higher scores when compared to the HD population (P < 0.0001) 
in this prospective observational study.
236
 
Lastly, the difference in the quality of life between HD and PD treatments was also 
tested. Turkmen et al. studied 154 dialysis patients (64 PD and 90 HD patients) for 
quality of life, and indicated that PCS and MCS scores were significantly higher in HD 
patients.
240
 Another multicenter study also supported the superiority of HD treatment in 
terms of PCS scores.
237
  This was not in line with another study by Harris et al. that 
indicated no significant difference between dialysis modalities in quality of life.
241
 Age 
and comorbid conditions might be major confounders that could affect quality of life.  
Sleep quality and depression have been also correlated with a low quality of life in 
several studies.
238,242
 Lee et al. studied 208 CKD patients, and  indicated that depression 
was associated with lower quality of life scores.
238
 Poor sleep quality was also related to a 
lower quality of life in dialysis patients.
242
 This was supported by another report.
243
 Poor 
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sleep quality, mental health, and quality of life were shown to be interrelated conditions 
in kidney patients.
200
 
2.3.2 Gaps in Existing Literature 
Since sleep apnea is common, under-diagnosed, and related to life-threatening 
complications, the factors related to the disease have been areas of interest for many 
researchers.
112,213
  Age, gender, and BMI are established risk factors for sleep apnea in the 
general population.
29
 However, determinants of sleep apnea in CKD patients have not 
been well studied. Several studies indicated that the traditional factors were not well 
correlated with sleep apnea in kidney patients.
213,244-247
 As a result, predictors of sleep 
apnea syndrome need to be explored in more detail in kidney patients. 
Depression has been associated with higher morbidity and mortality rates in dialysis 
patients.
248,249
 The condition has also been associated with low medication adherence in 
the dialysis population.
250
 Physician-diagnosed depression and questionnaire based 
diagnose were compared in a large multicentre dialysis patient cohort, and it was shown 
that depression was under-diagnosed.
251
 The link between early diagnosis and treatment 
of depression, and patient-oriented outcomes is yet to be discovered.
248
  
Assessment and management of modifiable risk factors for sleep disturbances, 
depression, and quality of life is important in improving health outcomes and patient 
satisfaction.
112,213,248,249 Risk factors for these conditions are not well-known in CKD 
patients.
244-247
 Further research is needed to establish algorithms for diagnosis and 
management of these comorbid conditions. Although use of the screening tools, such as 
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the BDI and SF-36, is recommended in the dialysis population, the implication of this 
practice for patient outcome is not clear. 
2.3.3 Objectives of the Study 
 
The main objective of this study was to identify factors associated with sleep quality, 
sleep apnea, depression, and quality of life in kidney patients. The point prevalence of 
sleeping problems, including sleep apnea and depression, was studied. The correlation 
between sleeping problems, depression, and quality of life was also examined. The 
association between quality of life with eGFR and Hb was tested. Objectives of the study 
also included a comparison of correlates of poor sleep quality in the dialysis and non-
dialysis groups. A summary of primary and secondary objectives follows: 
2.3.3.1 The Primary Objective 
     1. To determine factors associated with sleep disturbances, depression, and quality of 
life among patients with chronic kidney disease. 
2.3.3.2 Secondary Objectives 
 
1. To assess the prevalence of sleeping problems, sleep apnea, and depression in 
CKD patients. 
2. To test the correlation between sleeping problems, depression, and quality of life. 
3. To test the association between e-GFR with sleeping problems and depression. 
4. To test the association between hemoglobin with MCS and PCS scores. 
5. To test the correlation between e-GFR with MCS and PCS scores. 
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6. To examine correlates of poor sleep quality in the dialysis and non-dialysis 
groups. 
2.3.4 The Hypothesis 
 
The cardiovascular disease risk has been reportedly high in patients with CKD
188
, and 
traditional and non-traditional cardiovascular disease risk factors need to be addressed in 
the management of these patients.
188
 Psychosocial stress and physical inactivity are 
among traditional cardiovascular risk factors.
188
 Since modifiable risk factors have been 
linked to negative health outcomes,
252
 it was recommended that traditional cardiovascular 
disease risk factors be assessed in all CKD patents.
188
 Assessment and modification of 
psychosocial factors and physical well-being twice a year, including depression, anxiety, 
and quality of life  is recommended in dialysis patients.
64
  
Since sympathovagal imbalance influences clinical phenomena such as hypertension, 
diabetes mellitus, CKD, depression, and sleeping problems, there should be correlations 
between these conditions. We hypothesized that sleeping problems and depression 
correlate with the degree of kidney dysfunction and hypertension, and these conditions 
might affect quality of life in CKD patients. As a result, sleep quality, depression, and 
quality of life should be inter-related in those with CKD. The prevalence of each of these 
conditions should be higher when kidney disease is more advanced, such as in dialysis 
stage. Estimated glomerular filtration rate was used for CKD definition and should be 
correlated with sleep quality and depression.  To test the factors associated with sleep 
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quality, sleep apnea, depression, and quality of life, we conducted a cross-sectional study. 
The hypothesis was summarized in the following page. 
1. We hypothesize that the prevalence of impaired sleep will be higher in the group 
on dialysis than in those with less severe CKD. 
2. We hypothesize that the prevalence of sleep apnea will be higher in the group on 
dialysis than in those with less severe CKD. 
3. We hypothesize that the prevalence of depression will be higher in the group on 
dialysis than in those with less severe CKD. 
4. We hypothesize that sleep quality will be correlated with eGFR, blood pressure, 
and presence of diabetes.  
5. We hypothesize that poor sleep quality will be associated with poorer quality of 
life. 
6. We hypothesize that sleep apnea will be associated with poorer quality of life. 
7. We hypothesize that depression will be associated with poorer quality of life. 
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Chapter 3: METHODOLOGY 
 
This is a cross-sectional study of adult patients with stage 1 through 5 CKD recruited 
between September 2012 and December 2012. HD patients were recruited from the 
Health Sciences Centre, St. Clare’s Mercy, and Waterford Hospitals’ HD centres in St. 
John’s, Newfoundland and Labrador, Canada. Patients with CKD, with or without a 
transplant, were enrolled in the Waterford Hospital outpatient nephrology clinics. PD and 
home HD patients were also recruited from the Waterford Hospital outpatient clinics. 
Kidney dysfunction was defined by an e-GFR calculated with the MDRD formula. 
Inclusion criteria included (i) being an adult patient (18 years or older), (ii) having some 
degree of kidney dysfunction with an eGFR cut-off of 60 ml/min/1.73m², and (iii) living 
in the St. John’s area. Exclusion criteria included (i) severe vision and/or hearing 
problems that interfere with the informed consent process and (ii) choosing to decline 
research participation. 
This study was approved by the provincial Health Research Ethics Authority and 
Research Proposal Approval Committee of Eastern Health. Each patient was approached 
by a member of the care team to obtain initial consent before being approached by the 
researcher. The informed consent process was completed after sufficient information was 
given and written consent obtained by the primary investigator. The questionnaires were 
administered by the principal investigator, who read out the statements and asked the 
participants to choose the most appropriate response for his or her current condition. 
Consequently, the selected statement was circled. The questionnaires were self-
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administered by those who did not require any assistance. The duration of interviews 
ranged from 20 to 45 minutes.  
The instruments that were employed in this study were the PSQI,
14
 BQ,
17
 BDI,
184
 BDI-
FS,
187
 and SF-36.
15,190
 Each questionnaire was scored for each participant. BDI-FS 
instrument was scored by the principal investigator after the interview was completed. 
The attending nephrologist was notified if a patient’s results showed a significant 
depression risk and/or high risk for sleep apnea. A decision for a psychiatry consultation 
and/or sleep study order was at the discretion of the attending nephrologist. 
A case report form (Appendix A) was developed for this study, on which we recorded 
patient’s age, sex, race, marital status, weight, height, presence of diabetes mellitus, 
current CNS medication use, dialysis vintage, and details of the dialysis prescription, 
including recent predialysis weight and average interdialytic weight gain in the week 
prior to the study measurements. Several laboratory parameters were also recorded, and a 
detailed explanation is provided in the following pages. The patient’s sitting blood 
pressure prior to the interview was also recorded. Each participant was given a unique 
identification number to protect confidentiality. The inventory of participants and 
associated identification numbers were kept in a secure place. Electronic files were kept 
under password protection. 
3.1 Data Collection 
 
Baseline data collection following informed consent included administration of 
questionnaires, blood pressure measurements, and anthropometric measurements (weight, 
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height). Chart review was also performed for the parameters as described in the following 
pages. Demographic variables including age, gender, and marital status were registered 
for each participant. After data entry was completed, 15% of cases were randomly 
selected, and all variables related to these cases were rechecked. The rate for incorrect 
entry was 1%. 
3.2 Definitions of Exposures and Covariates 
3.2.1 Race 
 
Participants were divided into two groups— Caucasian or non-Caucasian—under the race 
category. Since only two participants were non-Caucasian, race was not tested as a 
predictor. 
3.2.2 Marital Status 
 
According to the information about marital status, participants were categorized into two 
groups. Those who were married or had a common-law partner were included in one 
group. Participants who were single, widowed, or divorced were included in the other 
group. The reason for this assignment was to test the significance of relationship status on 
sleep quality. 
3.2.3 Chronic Kidney Disease 
 
CKD was defined by an eGFR estimated by an MDRD
32
 approach. Kidney dysfunction 
was categorized with eGFR, according to the severity of damage as follows: stages 1 and 
2 (eGFR ≥ 60ml/min/1.73m²), stage 3 (eGFR 30—59 ml/min/1.73m²), stage 4 (eGFR 
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15—29 ml/min/1.73m²), and stage 5 eGFR (< 15ml/min/1.73m²). Those with eGFR ≥ 
60ml/min/1.73m² had either abnormal urine or kidney imaging tests. Patients were also 
further classified as dialysis and non-dialysis groups. Dialysis treatments included in-
center and home-based dialysis treatments: home-HD and peritoneal dialysis.  
3.2.4 Diabetes Mellitus 
 
Diabetes mellitus was defined as a binary variable (yes/no). Self-reported cases and those 
who were on either insulin or one of the oral anti-hyperglycemic agents were considered 
diabetic. Cases with type 1 and type 2 diabetes were included under one category. 
Detailed reports identifying all co-morbidities were not available, especially in non-
dialysis patients. As a result, only diabetes mellitus and hypertension were included as co-
morbid conditions. 
3.2.5 Obesity 
 
A BMI was calculated with the following formula: weight (Kg) / height² (m²). Obesity 
was defined using BMI, with values more than 30 Kg / m² considered obese. 
3.2.6 Smoking Status 
 
Patients were asked about their smoking status. Those who never smoked and those who 
smoked in the past, but quit were grouped in one category. Current smokers were grouped 
in the other category.  
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3.2.7 Blood Pressure Control 
 
Blood pressure recordings of more than 135/85 mmHg or less than 110/60 mmHg were 
considered abnormal. The sitting predialysis blood pressure was recorded for dialysis 
patients. Sitting blood pressure measurements before the doctor’s visit were also recorded 
for ambulatory care patients. Blood pressure was measured with an automated machine 
by a registered nurse or licensed practical nurse after a five-minute rest. If the reading for 
systolic blood pressure was ≥ 135 mmHg or diastolic blood pressure was ≥ 85 mmHg, 
blood pressure was considered high and poorly controlled. Furthermore, those with 
systolic blood pressure with less than 110 mmHg and/or diastolic blood pressure less than 
60 mmHg were also included in the low and poorly controlled blood pressure category. 
Those with values less than 135 mmHg and higher than 110 mmHg for systolic blood 
pressure, and less than 85 mmHg and higher than 60 mmHg for diastolic blood pressure 
were included in the well-controlled blood pressure category. 
3.2.8 The Mean Arterial Pressure 
 
The mean arterial pressure was calculated for each participant with the following formula: 
                                                            
Sitting systolic and diastolic blood pressures on the day of the interview were used in the 
calculation. 
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3.2.9 The Pulse Pressure 
 
The pulse pressure was calculated with the following formula: 
[                                                  
Sitting systolic and diastolic blood pressures on the day of the interview were used in the 
calculation. 
3.2.10 Central Nervous System Medication Users 
 
CNS medications included benzodiazepine hypnotics, non-benzodiazepine hypnotics, and 
antidepressants. Antipsychotics, anticonvulsant agents, and opiates were not registered. 
Only seven patients were on an antipsychotic treatment (five CKD and two PD patients), 
and not included under the CNS medication category. Opiate use was not included due to 
missing data. Data were not available to classify alcohol use either. Prescription data was 
taken from the medical charts, not by patient history. Medical data related to opiate and 
alcohol use were incomplete, especially for the non-dialysis group. 
3.2.11 Laboratory Data 
 
Laboratory data included parathyroid hormone (PTH), calcium (Ca), phosphate (P), 
albumin, glucose, hematocrit (Hct), hemoglobin (Hb), and e-GFR for non-dialysis group.  
Excluding PTH, the value closest in time to the interview within the window plus or 
minus three months was collected. Values within six months of the interview day were 
recorded for PTH. However, all values excluding PTH were within a one-month period 
for dialysis and transplanted patients.  Serum calcium level was corrected with the 
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following formula: serum calcium (mmol/L) + 0.02 * [40-patient’s serum albumin (g/L)]. 
PTH, Ca, P, and Hb have been associated with sleep quality in CKD patients as indicated 
in the literature review. 
3.2.12 Dialysis Status 
 
Dialysis status was also recorded in the following manner: dialysis positive group 
included those who were on HD or PD.  
3.2.13 Dialysis Vintage 
 
This variable was only applied to dialysis patients by recording the time, in days, since 
the first dialysis treatment started. 
3.2.14 The Vascular Access 
 
This variable was only applied to HD patients. The access type included arteriovenous 
(AV) fistula, arteriovenous graft, and catheter including temporary and permanent. The 
type of the vascular access was categorized as catheter and AV fistula in this study 
cohort, as none of our patients had an AV graft. Catheter access might be a marker for 
poorer overall health. 
3.2.15 Peritoneal Dialysis Modalities 
 
This variable was only applied to PD patients. Continuous ambulatory peritoneal dialysis 
(CAPD) and automated peritoneal dialysis were two modalities (APD) for PD patients.  
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3.2.16 The Interdialytic Weight Gain 
 
This variable was only applied to HD patients. The interdialytic weight gain (IWG) 
equals to sum of the net ultrafiltration per dialysis session in the last six dialysis sessions 
including the day of the interview divided by 6.  
3.2.17 The Sleep Quality 
 
A global score was obtained for each participant by adding the scores from seven 
components of the PSQI. Scores higher than 5 were considered to indicate poor sleep, 
while scores equal to or lower than 5 were considered good sleep. When the global score 
was examined as a continuous variable, higher scores indicated worse sleep quality, 
whereas lower scores suggested better sleep quality.  
3.2.18 Sleep Apnea 
 
The Berlin Questionnaire was used to assess the risk status for sleep apnea.
17
 The 
instrument indicated high or low risk for sleep apnea, and each category was assigned a 
dummy variable.  
3.2.19 The Beck Depression Inventory 
 
A cut-off value of 16 was employed in the current study for the BDI, and a global score 
of 4 or more was considered as positive for BDI-FS.
181,187
 The questionnaire was scored 
on the day of the administration. The attending nephrologist was notified about those with 
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positive test results for depression. A psychiatric referral was at the discretion of the 
physician. 
3.2.20 Quality of Life 
 
A license from QualityMetric was obtained for the administration of the SF-36 forms.
15
 
The QualityMetric Health Outcomes 
TM
 Scoring Software 4.5 was also provided by 
QualityMetric. A four-week recall form of the SF-36 version 2 was employed in this 
study. Scores were calculated using norms for Canada. An Excel database (Microsoft 
Corp, Seattle, WA, 2010) was used for initial data entry and data preparation for analysis. 
A conversion was made to a comma-separated value (CSV) format before the data was 
uploaded into the software. Original 0–100 scoring and norm-based scoring were 
performed with the Scoring Software 4.5. Subsequently, the relevant data were uploaded 
into an SPSS data file (SPSS, version 20.0, Chicago, IL). Eight health domains and two 
summary measures were calculated. The norm-based scores were included in the analysis 
due to the advantages that were mentioned previously.  
3.3 The Research Question Overview: Population, Comparison, Exposure, Outcome, 
and Time (PICOT) 
 
The PICOT approach was adopted for the development of the research question. The 
population consisted of adult CKD patients. Primary exposure was kidney dysfunction. 
Covariates included age, gender, BMI, diabetes mellitus, smoking, SDP, DBP, MAP, PP, 
blood pressure control, CNS medication use, Hb, and receiving dialysis treatment. Sleep 
quality, sleep apnea, depression, and quality of life were the main outcomes. The PSQI,
14
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BQ,
17
 BDI,
184
 BDI-FS,
181
 and SF-36 questionnaires
15
 were employed as measurement 
tools in this study. Since this was a cross-sectional study, exposures and outcomes were 
measured simultaneously. 
3.4 The Analytical Plan 
 
The analytical plan included descriptive and inferential statistics. Firstly, descriptive 
statistics for central tendency (mean, median, and mode), dispersion (minimum, 
maximum, and standard deviation), and distribution (skewness and kurtosis) were the 
initial steps for analysis. Consequently, mean values (standard deviation; SD) for 
normally distributed and median values (inter-quartile range; IQR) for non-normally 
distributed continuous variables were used to summarize the values. Frequencies 
(numbers) and proportions were used for categorical variables in the dialysis and non-
dialysis groups.   
Secondly, if the assumption of equal variances between the two groups was met, the 
initial step for the inferential statistics was the comparison of means for continuous 
variables with a student t-test; otherwise, a nonparametric test was employed for the 
comparison (Mann-Whitney U test). The Levene’s test was used to test the equal variance 
assumption with a significance level of 0.05. Frequency distributions for categorical 
variables were compared with the Pearson chi-square test between the groups. If the chi-
square test assumption was violated (all expected cells had to be more than 5, as degrees 
of freedom was 1 for a 2 x 2 table), Yates’ correction was planned to be a substitute for 
the Pearson test.  
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Thirdly, associations between poor sleep quality, risk of sleep apnea, and depression in 
the study cohort were sought with demographic characteristics and laboratory data. Age, 
gender, marital status, BMI, presence of diabetes mellitus, current smoking status, level 
of blood pressure control, MAP, PP, Hb, eGFR, stage of CKD, BQ, BDI, BDI-FS,  PCS, 
and MCS have been tested for an association with sleep quality. Further, associations of 
PCS and MCS scores with sleep quality, risk for sleep apnea, depression, and all 
covariates were tested using Spearman’s correlation coefficient tests. 
Furthermore, the hypothesis of “sleep quality” can be predicted by age, gender, BMI, 
presence of diabetes, current smoking status, level of blood pressure control, MAP, PP, 
SBP, DBP, CNS medication use, dialysis treatment status, stage of CKD, eGFR, Hb, 
BDI, BQ, PCS, and MCS” was tested in this study cohort. Since there was only one 
outcome variable, simple linear or nonlinear regression could have been employed. The 
outcome variable was dichotomous; as a result, logistic regression models were employed 
that accommodated multiple predictors. Since a non-linear model was employed, 
confidence intervals that included 1 were considered as non-significant. Model 
significance was tested by the Omnibus test, Hosmer-Lemeshow test and -2loglinear 
likelihood ratios (-2LLR). Cox-Snell R² and Nagelkarke R² were considered as the 
equivalent to R² in the linear regression. Significance of individual coefficients was tested 
by the Wald statistic technique, and odds ratios with 95% confidence intervals (CI) were 
obtained.  
Assumptions were tested, and residual analysis was performed to evaluate the model. 
Since the linearity assumption was violated for MCS scores, quartiles ranges were used to 
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categorise the variable. Category 1 (percentile < 25%) included values less than 49.4, 
category 2 (percentile 25%–50%) included values between 49.4 and 55.5, category 3 
(percentile 50%–75%) included values between 55.5 and 59.5, and category 4 (percentile 
> 75%) included 59.5 and 73. Subsequently, MCS score was used as a categorical 
variable in the multivariate and reduced models. A difference contrast (reverse Helmert 
contrast) method was selected to compare the categories of MCS with the mean of the 
previous categories of the variable in the logistic regression technique.  
Two-sided tests were employed with a significance level of 0.05. Imputation for missing 
data was not performed. The percentage of missing data was between 0% (age, gender, 
dialysis status, the PSQI, and the BQ questionnaires) and 11% (phosphate) in the study 
cohort. Finally, subgroup analysis was performed for the dialysis and non-dialysis groups. 
Characteristics of the cohorts were examined. Further, comparisons between the groups 
with poor and good sleep quality were made. 
3.5 Statistical Analyses  
 
All data analyses were performed using IBM SPSS Statistics 20, Release Version 20.0 
(SPSS, Inc., 2011, Chicago, IL, www.spss.com).  
3.6 Preparing the Data  
 
The information was compiled in Excel spread-sheets initially. Before the raw data was 
transferred to SPSS, the data set was cleaned, recoded, and prepared for analysis. The 
correlation analysis included the presence of depression, high risk for sleep apnea, poor 
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sleep quality, and PCS and MCS scores as outcome variables. One outcome variable and 
19 explanatory variables were employed in the univariate logistic model (table 3.9). The 
dependent variable was the nominal binary variable (dichotomous), while 50% of the 
independent variables were categorical.  
In the Logistic Models, the outcome variable was expressed as good or poor sleep quality 
with a threshold of 5 for the global PSQI score. As a result, a censoring dichotomy was 
used to produce two-level variables by a critical value for the outcome variable. A 
censoring dichotomy was also applied to BDI and BP control. The rest of the categorical 
response variables had a natural dichotomy, and all were coded as dummy numbers “0” 
or “1”. No modification took place for two continuous variables; nevertheless, the 
distribution and outliers were determined by using a histogram. The SF-36, BDI, and 
BDI-FS questionnaires were scored and registered as quantitative continuous variables in 
the dataset. The detailed explanation of the coding process was provided in the data view 
of SPSS. 
The first step was to test the model fit reliability to indicate if at least one of the predictors 
was related to the outcome. Afterwards, hypothesis testing was performed. Lastly, the 
assumptions for the logistic regression were tested to assure the results were valid and 
generalizable to other populations. The details are given in the results section. 
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Chapter 4: RESULTS 
4.1 Descriptive Statistics 
Demographics and patient population: A total of 303 patients (125 females, 178 males 
with mean age 62.7 ± 14.5 years) were included in this cross-sectional study (please see 
table 4.1). The overall participation rate, which was defined as the total number of 
patients who did not refuse consent divided by the total number of patients who were 
approached by a team member on that particular day, was 35.2% in ambulatory care 
patients and 50% in hemodialysis patients. The total of 202 patients (86 females, 116 
males, mean age 63.8 ± 14.4) had non-dialysis CKD, and 18 patients had a kidney 
transplant. A total of 101 patients (39 females, 62 males, mean age 60.6 ± 14.4) were on 
dialysis; 7 patients were on PD, 2 patients were on home HD and 92 patients were in-
centre HD treatments. The vast majority of the participants (n: 301; 99%) were 
categorized as Caucasian, while only two people were non-Caucasian. A total of 186 
(61.4%) participants (65; 64.4% in the dialysis group and 121; 59.9% in the non-dialysis 
group) were married or had a common-law partner. 
Participants were also divided into five groups according to eGFR. Stage 1 and 2 needed 
to be collapsed into one category as eGFR was only reported as more than 
60ml/min/1.73m², and it was not possible to further specify the results as stage 1 or 2. A 
total of 39 patients were in stage 1 and 2: 79 in stage 3, 68 in stage 4, and 112 in stage 5. 
Five people were missing a valid eGFR. 
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CNS medication users were also registered. A total of 94 (31%) patients were on 
hypnotics and/or antidepressant treatments. In the dialysis group 53 (52.47%) and in the 
non-dialysis group 41 (20.2%) participants were on a CNS medication. The Pearson Chi-
square test indicated a significant difference between these groups (P: 0.0001). The 
dialysis group had a higher frequency in terms of a CNS medication use. 
Of 303 participants, 293 patients had a blood pressure measurement and 76 (25.1%) 
patients were in the well-controlled category. A total of 166 (55%) patients had 
hypertension, and 51 (17%) patients had hypotension in the study cohort. In the dialysis 
group, 20 patients had normal blood pressure, while the number of patients with normal 
blood pressure was 56 in the non-dialysis group. The dialysis and non-dialysis groups 
were not significantly different (P: 0.13) in terms of the proportion of patients with well-
controlled blood pressure.  
An arteriovenous fistula was the method of choice for a vascular access in most of the HD 
patients. A total of 55 (58%) HD patients had an AV fistula, while 39 (42%) patients had 
a catheter. Of seven PD patients, three patients were on APD treatment, while four 
patients were on CAPD. Please see comparisons between the dialysis and non-dialysis 
groups in the table 4.1 for patient characteristics, and table 4.2 for laboratory data. 
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Table 4.1 Baseline characteristics of the participants divided by dialysis status 
Variable Entire cohort 
(mean  ± SD) 
The dialysis 
group 
(mean  ± SD) 
The non-
dialysis group 
(mean  ± SD) 
P
a
 
N 303 101 202  
Age (years) 62.7 ± 14.5 60.6 ± 14.4 63.8 ± 14.4 0.07 
BMI (kg/m²) 29.8 ± 6.5 29.4 ± 5.9 30 ± 6.7 0.43 
MAP (mmHg) 91.4 ± 13.4 94.5 ± 16.8 89.7 ± 11 0.022
c 
PP (mmHg) 72.4 ± 21.6 76.2 ± 23.2 70.5 ± 20.4 0.03 
Variable Entire cohort 
N (%) 
The dialysis 
group 
N (%) 
The non-
dialysis group 
N (%) 
P
a
 
Female gender; 
n (%) 
125 (41.2%) 86 (43%) 39 (39%) 0.50 
Married or had 
a common law 
partner; n (%) 
186 (68%) 65 (64%) 121 (69%) 0.7 
Caucasian; n 
(%) 
301 (99.3%) 100 201 1
b
 
Diabetes; n (%)
 141 (46.7%) 53 (52.5%) 88 (43.8%) 0.15 
CNS medication 
user; n (%) 
94 (31%) 53 (52%) 41 (20%) 0.0001 
Smoking; n (%)
 28 (9.2%) 12 (11.8%) 16 (7.9%) 0.26 
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Blood pressure 
Normal; n (%) 
High; n (%) 
Low; n (%)
 
 
76 (25%) 
 
166 (55%) 
 
51 (17%) 
 
20 (20%) 
 
65 (65%) 
 
16 (16%) 
 
56 (28%) 
 
101 (50%) 
 
35 (17%) 
0.13 
Abbreviations: BMI: body mass index; CNS: central nervous system; MAP: mean arterial pressure; PP: 
pulse pressure.  
a
: P value indicates comparison between dialysis and non-dialysis groups; 
b
: indicates 
continuity correction; 
c
: indicates Mann Whitney U test. 
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Table 4.2 Summary of the laboratory parameters 
Variable Entire cohort 
(mean ± SD) 
The dialysis 
group 
(mean ± SD) 
The non-
dialysis group 
(mean ± SD) 
P
a
 
e-GFR 
ml/min/1.73m² 
21 (7-41)
c 
6.2 ± 2.6 36.6 ± 16.3 0.0001 
Hb (g/L) 119 ± 22.3 107 ± 20 126 ± 20 0.0001
b 
Hct 36.3 ± 8.8 33 ± 3.7 38.1 ± 10.1 0.0001
b 
Albumin(g/L) 34.7 ± 4.9 32 ± 5 35.9 ± 4.3 0.0001 
PTH 
(pg/ml) 
200 (99-475)
c 
635 ± 570 148 ± 118 0.0001
b 
Calcium
d 
(mmol/L) 
2.2 ± 0.67 2.38 ± 0.18 2.11 ± 0.8 0.88
b
 
P (mmol/L) 1.4  ±  0.4 1.8 ±  0.5 1.2 ± 0.3 0.0001
b 
Glucose 
(mmol/L) 
6.1 (4.9-8.6)
c 
8.6 ± 7.5 7.1 ± 3.3 0.3
b 
Abbreviations: eGFR: estimated glomerular filtration rate; Hb: hemoglobin; Hct: hematocrit; PTH: 
parathyroid hormone; P: phosphate. 
a: 
P value indicates comparison between dialysis and non-dialysis 
groups; 
b
: Indicates Mann Whitney U test; 
c
: Indicates median (interquartile range), 
d
: Indicates corrected 
calcium. 
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Sleep quality was evaluated with the PSQI as categorical and continuous variables. All 
participants completed the survey. A total of 117 participants (39%) were labeled as poor 
sleepers. Among those on a dialysis treatment, 47 (47%) patients were identified as poor 
sleepers whereas the non-dialysis group had 70 (35%) patients with poor sleep status. The 
Pearson Chi-square test was employed to test the difference in frequencies between the 
groups. There was a statically significant difference with a higher frequency in the 
dialysis group (P: 0.05). 
A total of 21 non-dialysis CKD respondents and 9 dialysis respondents reported that they 
had been diagnosed with and/or treated for sleep apnea. The Berlin Questionnaire 
indicated high risk for sleep apnea in 157 (51.8%) patients in the study cohort. In the 
dialysis group, 56 (55%) participants were classified as high-risk while in the CKD 
group, 101 (50%) patients indicated high-risk status for sleep apnea. The frequency was 
not significantly different between the groups (P: 0.37). 
The BDI was used for depression screening in this study. Only two participants did not 
complete the survey. The tool was administered to a total of 301 respondents (mean score 
5.19 ± 5.34). A total of 13 patients were classified as depressive (10 in the dialysis group 
and 3 in the non-dialysis group). There was a significant difference between the groups in 
the prevalence of depression with the BDI (P: 0.002 with continuity correction). The 
BDI-FS was positive in 28 respondents (9.24%). There was also a significant difference 
in the prevalence of depression between the dialysis and non-dialysis groups (P: 0.005) 
using the BDI-FS. Thus, the dialysis group included a higher proportion of depressive 
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patients, according to the questionnaires. The table 4.3 summarizes the results of the 
questionnaires. 
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Table 4.3 Summary of the questionnaire scores 
Variable Entire cohort 
(mean  ± SD) 
The dialysis 
group 
(mean  ± SD) 
The non-dialysis 
group 
(mean  ± SD) 
P value  
PSQI 4 (2-8)
d 
5.9  ± 4.2 4.9  ± 3.7 0.02 
BDI 4 (2-7)
d 
7.9  ± 7.1 3.9  ± 3.5 0.0001
c 
BDI-FS 1.07 ± 1.9 1.7  ± 2.5 0.8  ± 1.6 0.0001
c 
PCS 42 ± 10 39.8 ± 10 43.6 ± 10.7 0.004 
MCS 53 ± 9 49.9 ± 11 55.3 ± 7.5 0.0001c 
PF 46 (33-54)
d 
39.9 ± 11.5 45.5 ± 10.7 0.0001 
RP 39 (30-57)
d 
37.9 ± 12.1 43.1 ± 13.6 0.001c 
BP 52 (38-62)
d 
49.7 ± 12.6 50.6 ± 11.4 0.53 
GH 50 (40-55)
d 
45.2 ± 10.3 49.6 ± 9.8 0.0001 
VT 47 (35-53)
d 
43.4 ± 11.2 44.6 ± 11 0.34 
SF 57 (37-57)
d 
39.9 ± 15.1 51.1 ± 10.2 0.0001
c 
RE 56 (46-56)
d 
48.8 ± 9.5 53.7 ± 5.4 0.0001
c
 
MH 58 (48-61)
d 
51.6 ± 11.8 55.5 ± 9.4 0.006
c 
Variable Entire cohort 
N (%) 
The dialysis 
group 
N (%) 
The non-dialysis 
group 
N (%) 
P value  
PSQI 
categorical 
(score >5) 
117 (39) 47 (47%) 70 (35%) 0.05 
BQ 157 (51.8%) 56 (55%) 101 (50%) 0.37 
BDI categorical 13 (4%) 10 (10%) 3 (1%) 0.002
b 
BDI-FS 
categorical 
28 (9%) 16 (16%) 12 (6%) 0.005 
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Abbreviations: BP: Bodily Pain; BQ: Berlin Questionnaire; BDI: Beck Depression Inventory; BDI-FS: 
Beck Depression Inventory Fast Screening; GH: General Health; MCS: Mental Component Summary; MH: 
Mental Health; PCS: Physical Component Summary; PF: Physical Functioning; PSQI: Pittsburgh Sleep 
Quality Index; RE: Role Emotional; RP: Role Physical; SF: Social Functioning VT: Vitality. 
b
: Indicates 
continuity correction; 
c
: Indicates Mann Whitney U; 
d
: Indicates median (interquartile range). 
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Normalized scores from the eight scales and two summary measures of the SF-36 
questionnaire are displayed in the table 4.3. Only two participants did not complete the 
survey. PF, RP, and VT normalized scores were lower than the general population mean 
of 50 in the study cohort. Additionally, PCS scores were lower while MCS scores were 
about the same with a normal mean of 50 (42 ± 10 versus 53 ± 9 for PCS and MCS, 
respectively). Excluding BP and VT, all of the scores of scales were significantly lower in 
the dialysis group when compared to the non-dialysis group. PCS and MCS scores were 
also significantly lower in the dialysis group.  
The distribution of the continuous variables was tested using histograms, and a normal 
curve was displayed on each graph. Median and interquartile ranges were used for non-
normally distributed data, while mean and standard deviation were used in the normally 
distributed data. Please see the following pages for selected figures that indicate 
distribution of continuous variables including the PSQI, PCS, MCS, and BDI scores 
(figures 4.1, 4.2, 4.3, and 4.4, respectively). The PSQI and BDI scores' distributions were 
slightly positively skewed. 
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 Figure 4.1 A histogram displaying the PSQI global score distribution in the  study   
cohort 
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      Figure 4.2 A histogram displaying the PCS score distribution in the study cohort 
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    Figure 4.3 A histogram displaying the MCS score distribution in the study cohort 
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   Figure 4.4 A histogram displaying the BDI score distribution in the study cohort 
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The distribution of CKD stages in the study cohort was also examined. The majority of 
the study cohort consisted of patients with stage 5 CKD (37.6%). Stage 1 and 2 were 
collapsed into one category and only constitute 13% of the study cohort (please see the 
figure 4.5). 
 
 
 
 Figure 4.5 A pie chart displaying the stages of CKD in the study cohort 
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4.2 Correlation Analyses 
 
Correlations of sleep quality, sleep apnea, depression, and quality of life with covariates 
were performed. 
4.2.1 Associations for Sleep Quality 
 
Impaired sleep was more common in females (P: 0.0001). Those who were married or 
had a common-law partner were less likely to have a poor sleep quality (P: 0.01). High 
risk for sleep apnea was significantly higher in those with poor sleep quality (P: 0.02). 
Patients with depression were more likely to have a poor sleep quality, whereas those 
with good sleep quality had significantly higher MCS scores. PCS scores were slightly 
higher in the good sleepers, but did not reach a statistically significant level (P: 0.07). 
Please see table 4.4 for complete results. 
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Table 4.4 Associations between sleep quality and covariates 
Abbreviations: BQ:  Berlin Questionnaire; BDI: Beck Depression Inventory; BDI-FS: the Beck Depression 
Inventory Fast Screening BMI: body mass index; CKD: chronic kidney disease; eGFR: estimated 
glomerular filtration rate; Hb: hemoglobin; MAP: mean arterial pressure; MCS: Mental Component 
Summary; PP: pulse pressure; PCS: Physical Component Summary; PSQI: the Pittsburgh Sleep Quality 
Index.
  a
: indicates Mann Whitney U test. 
Variable PSQI global score  ≥ 
5 
PSQI global score  < 
5 
P value 
Age (mean ±SD) 63.2 ± 14.9 62.3 ± 14.2 0.6 
Gender (female); n 
(%) 
65 (55%) 60 (32%) 0.0001 
Married or common 
law partner; n (%) 
59 (58%) 127 (73%) 0.01 
BMI (Kg/m²)  
(mean ± SD) 
29.7 ± 7.2 29.8 ± 5.8 0.9 
Diabetes positive; n 
(%) 
57 (48%) 84 (45%) 0.5 
Current smokers; n 
(%) 
14 (12%) 14 (7%) 0.19 
Blood pressure  
 
Controlled (number, 
%) 
High (number, %) 
Low (number, %) 
 
 
 
32 (28%) 
57 (50%) 
25 (22%) 
 
 
44 (25%) 
109 (61%) 
26 (15%) 
0.13 
MAP mmHg (mean 
±SD) 
91.2 ± 15.3 91.4 ± 12.1 0.6 
PP mmHg (mean 
±SD) 
71.7 ± 23.7 72.8 ± 20 0.7 
Hb g/L(mean ±SD) 119.2 ± 18 122 ± 19 0.2 
eGFR ml/min/1.73 m² 
(mean ±SD) 
24.8 ± 20.6 27.2 ± 19 0.3 
Stage of CKD 
 
Stage1+2 (number, 
%) 
Stage3 (number, %) 
Stage4 (number, %) 
Stage5 (number, %) 
 
 
 
17 (15%) 
25 (22%) 
21 (18%) 
51 (45%) 
 
 
22 (12%) 
54 (29%) 
47 (26%) 
61 (33%) 
0.11 
BQ high risk; n (%) 70 (60%) 87 (47%) 0.02 
BDI (mean ±SD) 7.1 ± 6.9 3.9 ± 3.4 0.0001 
BDI-FS (mean ±SD) 1.5 ± 2.5 0.7 ± 1.4 0.0001 
PCS (mean ±SD) 40.9 ± 10.1 43.1 ± 10.8 0.07 
MCS (mean ±SD) 50.1 ± 10.3 55.5 ± 7.6 0.0001
a 
 
 
79 
 
4.2.2 Associations for Sleep Apnea 
 
Those with a high risk for sleep apnea were younger and had a higher BMI and MAP 
values (P: 0.02 for age, P: 0.0001 for BMI, and P: 0.01 for MAP). Patients with 
depression and poor sleep quality were also more likely to be in the high risk category for 
sleep apnea. High risk for sleep apnea was also associated with low PCS and MCS 
domain scores. Please see table 4.5 for details. 
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Table 4.5 Associations between sleep apnea and covariates 
Variable High risk for sleep 
apnea 
Low risk for sleep 
apnea 
P value 
Age (mean  ± SD) 60.7 ± 13.3 64.7 ± 15.4 0.02 
Gender (female); n 
(%) 
61 (38%) 64 (44%) 0.3 
Married or common 
law partner; n (%) 
97 (70%) 89 (65%) 0.4 
BMI (Kg/m²) (mean 
± SD) 
31.4 ± 7.1 28.1 ± 5.1 0.0001
a 
Diabetes positive; n 
(%) 
78 (50%) 63 (43%) 0.2 
Current smokers 15 (9%) 13 (9%) 0.8 
Blood pressure  
 
Controlled; n (%) 
High; n (%) 
Low; n (%) 
 
 
 
38 (25%) 
94 (60%) 
23 (15%) 
 
 
38 (27%) 
72 (52%) 
28 (20%) 
0.3 
MAP (mean ± SD) 93.2 ± 13.3 89.2 ± 13.2 0.01 
PP (mean ± SD) 73.5 ± 22.7 71.1 ± 20.1 0.3 
Hb (mean ± SD) 120.9 ± 19.4 121.2 ± 18.3 0.9 
eGFR (mean ± SD) 25.9 ± 19.9 26.7 ±  19.4 0.8 
Stage of CKD 
 
Stage1+2; n (%) 
Stage3; n (%) 
Stage4; n (%) 
Stage5; n (%) 
 
 
22 (14%) 
34 (22%) 
38 (25%) 
61 (39%) 
 
 
17 (12%) 
45 (31%) 
30 (21%) 
51 (36%) 
0.3 
PSQI (mean ± SD) 5.9 ± 4.1 4.4 ± 3.5 0.001
a 
BDI (mean ±SD) 6.2 ± 5.7 4.1 ± 4.5 0.001
 
BDI-FS (mean ± SD) 1.4 ± 2.2 0.6 ± 1.4 0.0001
a 
PCS (mean ± SD) 41.1 ± 10 43.5 ± 11.1 0.05
 
MCS (mean ± SD) 51.2 ± 9.7 55.7 ± 7.8 0.0001
a 
Abbreviations: BDI: the Beck Depression Inventory; BDI-FS: the Beck Depression Inventory Fast 
Screening; BMI: body mass index; CKD: chronic kidney disease; eGFR: estimated glomerular filtration 
rate; Hb: hemoglobin; MAP: mean arterial pressure; MCS: Mental Component Summary; PCS: Physical 
Component Summary; PP: pulse pressure; PSQI: the Pittsburgh Sleep Quality Index. 
a
: indicates Mann 
Whitney U test. 
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4.2.3 Associations for Depression 
 
Depression was associated with younger age and female gender (P: 0.01 for age and P: 
0.01 for gender). Advanced kidney disease and poor sleep quality were also associated 
with depression (P: 0.005 for eGFR, P: 0.02 for stage of CKD, and P: 0.0001 for sleep 
quality). MCS scores were significantly higher in the non-depressive patients (33.7 ± 11.5 
for depressive group and 54.4 ± 7.8 for non-depressive group, P: 0.0001). Diabetes 
mellitus and PCS clearly differed, but did not reach significance level due to power. 
Please see table 4.6 for details. 
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Table 4.6 Association between depression and covariates 
Variable Depression  positive Depression negative P value 
Age (mean ±SD) 53 ± 16 63 ± 14 0.01 
Gender (female); n 
(%) 
10 (77%) 115 (40%) 0.01
b 
Married or common 
law partner; n (%) 
7 (58%) 178 (68%) 0.6
b 
BMI (Kg/m²); (mean 
±SD) 
26.9 ± 6.9 29.9 ± 6.3 0.1 
Diabetes positive; n 
(%) 
8 (61%) 132 (46%) 0.4
b 
Current smokers; n 
(%) 
3 (23%) 25 (9%) 0.2
b 
Blood pressure  
 
Control; n (%) 
High; n (%) 
Low; n (%) 
 
 
 
3 (23%) 
8 (62%) 
2 (15%) 
 
 
73 (26%) 
156 (56%) 
49 (18%) 
0.9
c 
MAP (mean ±SD) 97.9 ± 21.05 91 ± 12.9 0.3
a 
PP (mean ±SD) 70.8 ± 18.7 72.5 ± 21.7 0.7 
Hb (mean ±SD) 133.9 ± 14.8 132.4 ± 15.4 0.7 
eGFR (mean ±SD) 11 ± 7.5 27 ± 19.8 0.005
a 
Stage of CKD 
 
Stage1+2; n (%) 
Stage3; n (%) 
Stage4; n (%) 
Stage5; n (%) 
 
 
0 (0%) 
0 (0%) 
3 (23%) 
10 (77%) 
 
 
39 (14%) 
79 (28%) 
64 (23%) 
101 (36%) 
0.02
c 
PSQI (mean ±SD) 10.6 ± 3.8 4.9 ± 3.7 0.0001 
BQ positive 11 (85%) 145 (50%) 0.03
b 
BDI-FS positive 12 (90%) 16 (5%) 0.0001
b 
PCS  (mean ±SD) 37.6 ± 10.6 42.6 ± 10.5 0.09 
MCS (mean ±SD) 33.7 ± 11.5 54.4 ± 7.8 0.0001
a 
Abbreviations: BDI-FS: Beck Depression Inventory Fast Screening; BQ: The Berlin Questionnaire; BMI: 
body mass index; CKD: chronic kidney disease; eGFR: estimated glomerular filtration rate;  Hb: 
hemoglobin; MAP: mean arterial pressure; MCS: Mental Component Summary; PCS: Physical Component 
Summary;  PP: pulse pressure, PSQI: Pittsburgh Sleep Quality Index. 
a
: indicates Mann Whitney U test; 
b
:indicates Continuity Correction; 
c
: indicates Likelihood Ratio. 
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4.2.4 Associations for Summary Measures of SF-36 
 
PCS and MCS were tested for association with various covariates using the Spearman’s 
coefficient of correlation (r values are in tables 4.7 and 4.8). Age, BMI, PP, the PSQI 
global scores, the BDI scores, and the BDI-FS scores were negatively correlated with the 
PCS scores. Further, Hb, eGFR, and MCS scores were positively correlated with the PCS 
scores. MAP did not show any significant correlation with PCS scores. Please see table 
4.7 and 4.8 for details. 
 
 
Table 4.7 Associations for PCS and covariates 
Variable r P value 
Age -0.24 0.0001 
BMI -0.15 0.009 
MAP 0.02 0.7 
PP -0.14 0.01 
Hb 0.32 0.0001 
eGFR 0.20 0.001 
PSQI -0.16 0.006 
BQ -0.12 0.02 
BDI -0.47 0.0001 
BDI-FS -0.26 0.0001 
MCS 0.60 0.03 
Abbreviations: BQ: Berlin Questionnaire; BDI: Beck Depression Inventory; BDI-FS: Beck Depression 
Inventory Fast Screening; BMI: body mass index; eGFR: estimated glomerular filtration rate; Hb: 
hemoglobin; MAP: mean arterial pressure; MCS: Mental Component Summary; PCS: Physical Component 
Summary; PP: pulse pressure; PSQI: Pittsburgh Sleep Quality Index. 
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Age, Hb, and eGFR were positively correlated with MCS scores (r: 0.14, P: 0.01 for age; 
r: 0.11, P: 0.04 for Hb; r: 0.19, P: 0.001 for eGFR). MAP, PSQI, BDI, and BDI-FS were 
negatively correlated with MCS scores. BMI and PP did not reach a significant level (P: 
0.77 for BMI and P: 0.82 for PP). 
 
 
Table 4.8 Associations for MCS and covariates 
 
 
 
 
 
 
 
Abbreviations: BQ: Berlin Questionnaire; BDI: Beck Depression Inventory; BDI-FS: Beck Depression 
Inventory Fast Screening; BMI: body mass index; eGFR: estimated glomerular filtration rate; Hb: 
hemoglobin; MAP: mean arterial pressure; MCS: Mental Component Summary; PCS: Physical Component 
Summary; PP: pulse pressure; PSQI: Pittsburgh Sleep Quality Index. 
 
 
 
 
 
 
 
Variable r P value 
Age 0.14 0.01 
BMI -0.01 0.77 
MAP -0.13 0.02 
PP 0.01 0.82 
Hb 0.11 0.04 
eGFR 0.19 0.001 
PSQI -0.28 0.0001 
BQ -0.26 0.0001 
BDI -0.52 0.0001 
BDI-FS -0.55 0.0001 
PCS 0.03 0.6 
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4.3 Inferential Statistics: 
4.3.1 Univariate Analysis 
 
Univariate analysis was performed as well as multivariate analysis, some of which were 
reduced models. The enter method was used for selecting variables. The outcome variable 
was sleep quality as determined by the PSQI score. Each step was tested for goodness of 
fit with 95% confidence intervals (CI).  
Univariate analysis was performed for each predictor variable, including age, gender, 
BMI, presence of diabetes, smoking, hemoglobin, stages of CKD, SBP, DBP, MAP, PP, 
CNS medication use, achievement of blood pressure control, dialysis treatment, eGFR, 
BDI, BQ, PCS, and MCS scores. The significance level was 0.1 for retention in the 
multivariate models. Age, BMI, presence of diabetes mellitus, current smoker status, 
stage of CKD, SBP, DBP, MAP, PP, blood pressure control status, hemoglobin, and 
eGFR were not significantly associated with sleep quality (P > 0.1). Thus, those factors 
were excluded from the multivariate analysis. In the univariate models, gender, CNS 
medication use, dialysis treatment, and BDI, BQ, PCS, and MCS scores reached a 
significant level of 0.1, and those covariates were included in the multivariate analysis 
(please see table 4.9 for the univariate analysis and table 4.11 for the multivariate 
analysis). 
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Table 4.9 The summary of univariate analysis for sleep quality 
Variables
a 
Exp (B) 95% CI P value 
Age 1.004 0.98–1.02 0.59 
Gender
b 2.6 1.6–4.2 0.0001 
BMI (Kg/m²) 0.99 0.96–1.03 0.88 
Diabetes
c 1.14 0.72–1.82 0.57 
Current smokers 1.67 0.77–3.6 0.19 
Hb 0.99 0.97–1 0.21 
Stages of CKD 1.12 0.9–1.4 0.3 
SBP 0.99 0.98–1 0.7 
DBP 1 0.98–1 0.8 
MAP 0.99 0.98–1.01 0.86 
PP 0.99 0.98–1.00 0.67 
CNS medication 
users
d 
0.29 0.18–0.495 0.0001 
Blood pressure 
High 
Low 
 
0.72 
 
1.3 
 
0.41–1.2 
 
0.6-2.6 
 
0.24 
0.44 
Dialysis
e 1.64 1.1–2.7 0.04 
eGFR  0.99 0.98–1.006 0.28 
BDI  1.14 1.1–1.2 0.0001 
BQ
f
 1.69 1.06–2.7 0.02 
PCS 0.98 0.96–1.003 0.08 
MCS 0.93 0.90–0.96 0.0001 
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Abbreviations: BQ: Berlin Questionnaire; BDI: Beck Depression Inventory; BDI-FS: Beck Depression 
Inventory Fast Screening; BMI: body mass index; CKD: chronic kidney disease; CNS: central nervous 
system; DBP: diastolic blood pressure; eGFR: estimated glomerular filtration rate; Hb: hemoglobin; MAP: 
mean arterial pressure; MCS: Mental Component Summary; PCS: Physical Component Summary; PP: 
pulse pressure; SBP: systolic blood pressure. 
a
: Logistic regression with enter method (P: 0.05) was 
performed to identify factors independently associated with sleep quality in the study cohort; 
b
: Indicator 
female gender; 
c
: Indicator presence of diabetes; 
d
: Indicator use of CNS medication; 
e
: Indicator receiving a 
dialysis treatment; 
f
: Indicator a positive result from the BQ.  
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4.3.2 Multivariate Analyses 
Firstly, the overall model fit was tested. The hypothesis was stated as follows:  
Table 4.10 Statements of the Null and Alternative Hypothesis 
H0
a
 
 
=  B1 = B2 = B3……… =  0 
Ha
b
  = At least one Bxc ≠ 0  
a
: Indicates the Null hypothesis; 
b
: Indicates the Alternative hypothesis; 
c
: Indicates any possible predictor 
being tested. 
 
The Wald chi-square test was significant in the null model, indicating that this model was 
better than no model at all. Since the Wald test has been associated with a risk for type 2 
error, model fit was also evaluated by additional tests. However, type 2 error is the risk 
for a non-significant result when in fact an association exists. Since we had a significant 
result, type 2 error risk did not exist in our models. The goodness of fit was also tested by 
the Omnibus test, Hosmer-Lemeshow test, as well as Cox-Snell R² and Nagelkarke R² 
values (P: 0.0001 for the Omnibus test, P: 0.68 for the Hosmer-Lemeshow test). Both P 
values supported model fit. The Hosmer-Lemeshow is considered most reliable in the 
presence of one predictor for every ten observations. In this analysis, the main outcome 
was sleep quality, and a total of 117 patients had poor sleep quality. The model could 
accommodate 11–12 predictors according to the rule. In the multivariate model, only 
seven predictors were tested.  
Cox-Snell R² and Nagelkarke R² values were used, neither of which reached one. The 
former was 0.17, and the latter was 0.23. Both values implied some correlation, but not a 
perfect fit.  
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Individual predictors were also tested by the Wald test. The multivariate analysis (please 
see table 4.11) did not reach a significant level (P < 0.05) for receiving dialysis treatment, 
depression, sleep apnea, and PCS scores. Subsequently, those were excluded in the 
reduced model.  
C index was 61.5% in step 0 and 68.6% in step 1. Predictive power of the model was 
increased by adding predictors, as the C index was improved by 7.1%. This increase was 
substantial and implied that at least one predictor had a strong association with the 
outcome variable. The ideal C-index is 100%, while the minimum acceptable limit is 
50%. 
To conclude, the results of the multivariate analyses indicated that CNS medication use 
was associated with a higher risk for having poor sleep quality (OR: 2.6, 95% CI: 1.4–4.9, 
P: 0.002 for CNS medication use). Being a female was associated with a 2.5-fold increase 
in risk for having poor sleep quality (OR: 2.5, 95% CI: 1.5–4.3, P: 0.0001). Having high 
MCS scores was tied to having a higher sleep quality. 
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Table 4.11 The Summary of multivariate analysis for sleep quality 
Variables
h 
Exp (B)  95% CI P value 
Gender
a 2.5 1.5–4.3 0.0001 
CNS meds 
users
b 
2.6 1.4–4.9 0.002 
Dialysis
c 0.99 0.5–1.8 0.99 
BDI 1.1 0.98–1.14 0.1 
BQ
d 1.3 0.8–2.3 0.2 
PCS 1 0.9–1.02 0.90 
MCS 
Category (1)
e 
Category (2)
f 
Category (3)
g 
 
1.3 
 
0.8 
 
0.4 
 
0.6–2.8 
 
0.4–1.6 
 
0.2–0.8 
0.06 
0.45 
 
0.58 
 
0.01 
Abbreviations: BQ: Berlin Questionnaire; BDI: Beck Depression Inventory; CNS: central nervous system; 
MCS: Mental Component Summary; PCS: Physical Component Summary. 
a
: Indicator female gender; 
b
: 
Indicator CNS medication use; 
c
: Indicator receiving dialysis treatment; 
d
: Indicator positive Berlin 
Questionnaire; 
e
: Indicates comparison of  less than 25%percentile with 25-50% percentile categories; 
f
: 
Indicates comparison of  25-50% percentile with 50-75% percentile categories;  
g
: Indicates comparison of  
50-75% percentile with more than 75% percentile categories; 
h
:Logistic regression with enter method (P: 
0.05) was performed to identify factors independently associated with sleep quality in the study cohort. 
 
 
The reduced models included gender, CNS medication use, and MCS scores. Female 
gender increases the risk for poor sleep quality, whereas high MCS domain scores and not 
receiving a CNS medication reduces the risk for impaired sleep. -2log likelihood values 
were registered to compare the full model with the reduced model. It is known that the 
value should decrease to justify a better model in the same dataset. -2log likelihood in the 
 
 
91 
 
multivariate analysis was 342, while it was 348.8 in the reduced model. There was a 
minimal increase, which might be neglected. 
 
Table 4.12 The Summary of reduced models for sleep quality 
Variables
a 
Exp (B) 95% CI P value 
Gender
b 2.6 1.5-4.3 0.0001 
CNS medication 
users
c 
3.1 1.8-5.5 0.0001 
MCS 
Category (1)
d 
Category (2)
e 
Category (3)
f 
 
1.03 
 
0.6 
 
0.3 
 
0.5-2 
 
0.3-1.2 
 
0.2-0.6 
0.003 
0.9 
 
0.1 
 
0.001 
Abbreviations: CNS: central nervous system; MCS: mental summary scale. 
a
: Logistic regression with enter 
method (P: 0.05) was performed to identify factors independently associated with sleep quality in the study 
cohort; 
b
: Indicator female gender; 
c
: Indicator using a CNS medication; 
d
: Indicates comparison of  less 
than 25%percentile with 25-50% percentile categories; 
e
: Indicates comparison of  25-50% percentile with 
50-75% percentile categories; 
f
: Indicates comparison of  50-75% percentile with more than 75% percentile 
categories. 
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4.3.3 Assumptions  
 
Finally, assumptions for the logistic regression were tested followed by the residual 
analysis. A sample was used to make an inference for the population. As a result, 
assumptions were needed to be met to generalize the results of the study. Several 
assumptions have been tested, including independence, linearity, and multicollinearity. 
4.3.3.1 Independence 
 
Independence of sample observations was met since it was a random sampling; therefore, 
the observed relationship may be generalizable. Nevertheless, dispersion was also tested 
to prove the independence of the observations.  
4.3.3.2 Linearity 
 
Log odds of success are the linear function of the outcome variable. PCS and MCS scores 
were two continuous variables that were included in the multivariate analysis. The 
interactions of the aforementioned continuous variables with logarithmic transformation 
of PCS and MCS values were used to test the linearity assumption with a critical P value 
of 0.05. PCS and log of PCS interaction indicated a P value of 0.07, thus, the assumption 
was not violated for PCS scores. However, the interaction for MCS scores was associated 
with a P value of 0.0001. As a result, the assumption was violated for MCS scores.   
There are two methods that might be used when the linearity assumption is violated: 
transforming metric variables to ordinal level or categorization and inter-category 
comparison. We used the second approach, as previously mentioned. MCS was 
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categorized into quartiles (25%, 50%, 75%, and 100%), and included in the multivariate 
models as a categorical variable. A difference method was used to compare categories. 
Please see the following pages for the summary of the results for the linearity assumption. 
                                    
Table 4.13 The linearity assumption for PCS and MCS 
 
    Exp(B)   P value 
PCS by log 
PCS 
.996 .075 
MCS by 
log MCS 
.986 .000 
Abbreviations: log: logarithmic transformation of the PCS scores. 
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4.3.3.3 Multicollinearity 
 
The linear regression model was used to generate collinearity statistics. Tolerance and 
variance inflation factor (VIF) were used to test the assumption. Values less than 10 for 
VIF, and more than 0.1 for tolerance were considered violations. All of the values were 
below the limits. Please see the table 4.15 for collinearity statistics. Since 
multicollinearity was not violated, predictor variables did not have significant correlation 
with each other. 
Table 4.14 The Summary of collinearity statistics 
Abbreviations: BDI: Beck Depression Inventory; BQ: Berlin Questionnaire; CNS: central nervous system; 
MCS: Mental Component Summary; PCS: Physical Component Summary; VIF: Variance Inflation Factor. 
 
      
 
 
 
                                      
Tolerance 
                                             
VIF   
Gender 0.96 1.03 
Dialysis treatment  0.81 1.23 
CNS medication 0.76 1.3 
BDI  0.57 1.77 
BQ high risk  0.91 1.09 
PCS 0.83 1.19 
MCS 0.69 1.43 
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4.3.4 Other Considerations Regarding the Logistic Regression  
4.3.4.1 Incomplete Information 
 
Cross tabulation was performed with the PSQI categories and all categorical predictors, in 
order to evaluate the number of observations in the each cell. The assumption of “only 
less than 20% of cells may have less than five observations” was tested, and met. Only 1 
cell had less than 5 observations, and it was the race category.  
4.3.4.2 Complete Separation 
 
This assumption was not tested as no explanatory variable was considered as a perfect 
predictor.  
4.3.4.3 Dispersion 
 
A multinomial logistic regression test was employed to calculate the Pearson’s chi-square 
goodness of fit and Deviance chi-square goodness of fit. The aforementioned tests are 
used to test independence. Values more than two signify over-dispersion while less than 
one indicates under-dispersion. In general, 1 is considered as the ideal value and shows 
that the model has no dispersion. Additionally, it indicates that no important covariate is 
missing and variables are not correlated.  
In our sample, we have found 1.02 and 1.18, using Pearson’s and Deviance methods, 
respectively. In our models, the assumption was not violated and coefficient estimates 
were stable. Please see the following page for the summary of the results for that 
assumption. 
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                                        The Pearson chi-square goodness of fit 
 
                                   
  
                                       The Deviance chi-square goodness of fit 
 
                                                           
                     
 
  Table 4.15 Pearson’s and Deviance Chi² Tests: Assumption for independence 
 
 Chi-Square Degree of freedom P value 
Pearson 
Deviance 
296.939 
342.108 
288 
288 
0.346 
0.016 
 
4.3.5 Residual Analysis 
 
An examination was made for outliers and leverage points to eliminate the possibility of 
the presence of unusual observations and influential data.  
4.3.5.1 Outliers 
 
Standardized residuals for outliers were performed. As a rule, a maximum of 5% of the 
sample size may be higher than 2 (5% of 303: 15.15 cases might be higher than 2). Case-
wise statistics for standardized residuals indicated 4 cases were higher than 2. Those 
records were rechecked for any mistake during data entry. Then, the second rule was 
tested: a maximum of 1% of the sample size may be more than 2.5. Only 3 cases could be 
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more than 2.5; however, none of the cases were more than 2.5. As a result, both 
assumptions were met.  
4.3.5.1 Leverage Points 
 
Cook’s distances for leverage points were also analyzed. A Cook’s distance value of more 
than 1 was considered as points that carried leverage points. Neither the Cook’s distance 
values, nor DF-Beta values, exceeded one. 
4.4 Subgroup Analyses 
 
The study cohort included the dialysis and non-dialysis groups. Each group was tested for 
associations between sleep quality and risk for sleep apnea, depression, quality of life, 
and covariates, including age, gender, BMI, diabetes, smoking, MAP, PP, blood pressure 
categories, Hb, albumin, PTH, Ca, and P. Dialysis vintage in days and interdialytic 
weight gain were also included as covariates in the dialysis group, while eGFR was tested 
as a covariate in the non-dialysis group. 
Of a total of 101 dialysis patients, 39 (39%) were female and 61 (61%) were male with a 
mean age of 60.5 ± 14.4. In the dialysis group, a total of 48 (48%) patients were poor 
sleepers, while a total of 56 (56%) patients had a high risk for sleep apnea, according to 
the BQ results. Those with poor sleep quality were more likely to be female and 
depressive. Further, MCS scores were significantly lower in the patients with impaired 
sleep. Please see the table 4.17 for the associations for sleep quality in the dialysis group. 
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Table 4.16 Baseline characteristics of patients divided by sleep quality in the dialysis 
group 
Variables Entire cohort PSQI global 
score  ≥ 5 
PSQI global 
score < 5 
P value 
N; n (%) 101 48 (48%) 53 (52%)  
Age; mean ±SD 60.5 ± 14.4 59 ± 15 61 ± 13 0.4 
Gender (female); 
n (%) 
39 (39%) 24 (50%) 15 (28%) 0.02 
BMI (kg/m²); 
mean ±SD 
29 ± 5 28 ± 5 29 ± 6 0.4 
Diabetes 
positive; n (%) 
53 (53%) 26 (54%) 27 (51%) 0.7 
Current 
smokers; n (%) 
18 (18%) 10 (21%) 8 (15%) 0.4
a 
MAP (mmHg); 
mean ±SD 
94 ± 16 95 ± 17 93 ± 15 0.5 
PP (mmHg); 
mean ±SD 
76 ± 23 74 ± 22 77 ± 24 0.6 
Blood pressure 
 
Normal; n (%) 
High; n (%) 
Low; n (%) 
 
 
28 (28%) 
66 (66%) 
7 (7%) 
 
 
18 (37%) 
28 (58%) 
2 (4%) 
 
 
10 (18%) 
38 (72%) 
5 (9%) 
0.08
b 
Vintage(days); 
mean ±SD 
1009 ± 952 979 ± 1012 1035 ± 904 0.8 
IWG (ml); mean 
±SD 
1751 ± 827 1701 ± 1007 1727 ± 642 0.7 
Hb; mean ±SD 107 ± 20 106 ± 22 107 ± 18 0.9 
Albumin; mean 
±SD 
32 ± 5 32 ± 4 32 ± 5 0.9 
PTH; mean ±SD 635 ± 570 635 ± 534 635 ± 606 0.9 
Calcium
d
; mean 
±SD 
2.2 ± 0.67 2.4 ± 0.2 2.3 ± 0.2 0.06 
P; mean ±SD 1.8 ± 0.4 1.8 ± 0.4 1.7 ± 0.4 0.2 
Glucose; mean 
±SD 
8.6 ± 7.5 8 ± 5 9 ± 9.2 0.4 
BDI; mean ±SD 7.8 ± 7.1 9.9 ± 8.8 5.9 ± 4.1 0.09
c 
BDI-FS; mean 
±SD 
1.6 ± 2.4 2.3 ± 3 1 ± 1.5 0.04
c 
BQ; n (%) 56 (56%) 28 (58%) 28 (53%) 0.5 
PCS; mean ±SD 39.8 ± 10 39 ± 8 40 ± 11 0.7
c 
MCS; mean ±SD 49 ± 11 46 ± 11 53 ± 9 0.007
c 
Abbreviations: BDI: Beck Depression Inventory; BDI-FS: Beck Depression Inventory Fast Screening; 
BMI: body mass index; BQ: Berlin Questionnaire; eGFR: estimated glomerular filtration rate; Hb: 
hemoglobin; IWG: inter dialytic weight gain; MAP: mean arterial pressure; MCS: Mental Component 
Summary; PCS: Physical Component Summary; P: phosphate; PP: pulse pressure; PSQI: Pittsburgh Sleep 
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Quality Index. 
a
: Indicates continuity correction; 
b
: Indicates likelihood ratio; 
c
: Indicates Mann Whitney U 
test;
d
: Indicates corrected calcium. 
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In a total of 202 non-dialysis patients, 86 patients were female, and mean age was 64 ± 
14. A total of 70 (35%) patients had an impaired sleep. Female gender, depression, and 
high risk for sleep apnea were associated with impaired sleep. Lower MCS scores were 
also correlated with higher risk for poor sleep quality. Patients with an abnormal blood 
pressure had an increased risk for sleep disturbances according to the results. Table 4.18 
shows correlation of sleep quality with various patient characteristics. 
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Table 4.17 Baseline characteristics of patients divided by sleep quality in the non-
dialysis group 
Variables Entire cohort PSQI global 
score ≥ 5 
PSQI global 
score < 5 
P value 
N; n (%) 202 70 (35%) 132 (65%)  
Age; mean ±SD 64 ± 14 65.5 ± 14.4 62.8 ± 14.3 0.2 
Gender (female); 
n (%) 
86 41 (59%) 45 (34%) 0.001 
BMI (kg/m²); 
mean ±SD 
30 ± 6 30 ± 8 29 ± 5 0.6 
Diabetes positive; 
n (%) 
88 32 (46%) 56 (43%) 0.7 
Current 
smokers; n (%) 
16 5 (7%) 11 (8%) 0.9
b 
MAP (mmHg); 
mean ±SD 
89.7 ± 10 88.6 ± 13.2 90.2 ± 9.5 0.3 
PP (mmHg); 
mean ±SD 
70.4 ± 20.4 69.5 ± 24.6 70.4±17 0.6 
Blood pressure 
 
Normal; n (%) 
High; n (%) 
Low; n (%) 
 
 
56 (29%) 
101 (53%) 
35 (18%) 
 
 
18 (27%) 
30 (45%) 
19 (28%) 
 
 
38 (30%) 
71 (57%) 
16 (13%) 
 
 
0.03 
eGFR 
ml/min/1.73m²; 
mean ±SD 
36 ± 16 38 ± 17 35 ± 15 0.3 
Hb; mean ±SD 126 ± 19 125 ± 20 127 ± 19 0.4 
Albumin; mean 
±SD 
35.9 ± 4.3 36 ± 4.6 35.9 ± 4.2 0.9 
PTH; mean ±SD 148 ± 118 165 ± 133 141 ± 111 0.2 
Calcium
c
; mean 
±SD 
2.11 ± 0.8 2.4 ± 1.4 2.4 ± 1.2 0.17 
P; mean ±SD 1.2 ± 0.2 1.2 ± 0.3 1.2 ± 0.2 0.9 
Glucose; mean 
±SD 
7.1 ± 3.2 6.9 ± 2.9 7.2 ± 3.4 0.5 
BDI; mean ±SD 3.8 ± 3.5 5.2 ± 4.3 3.1 ± 2.8 0.0001
a 
BDI-FS; mean 
±SD 
0.7 ± 1.6 1.1 ± 1.9 0.6 ± 1.3 0.005 
BQ; n (%) 101 43 (61%) 58 (44%) 0.02 
PCS; mean ±SD 43 ± 10 42.4 ± 10.8 44.2 ± 10.6 0.2 
MCS; mean ±SD 55 ± 7 52.7 ± 8.1 56.5 ± 6.8 0.001 
Abbreviations: BDI: Beck Depression Inventory; BDI-FS: Beck Depression Inventory Fast Screening; 
BMI: body mass index; BQ: Berlin Questionnaire; eGFR: estimated glomerular filtration rate; Hb: 
hemoglobin; MAP: mean arterial pressure; MCS: Mental Component Summary; PCS: Physical Component 
Summary; P: phosphate; PP: pulse pressure; PSQI: Pittsburgh Sleep Quality Index. 
a
: Indicates Mann 
Whitney U test; 
b
: Indicates continuity correction; 
c
: Indicates corrected calcium. 
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Chapter 5: DISCUSSION 
5.1 Discussion of Results 
 
This cross-sectional study included a total of 303 CKD patients from the St John’s area. 
The summary of our findings are as follows: (1) MAP, PP, PTH, and P were significantly 
higher in the dialysis group; (2) PCS and MCS domains of SF-36 were lower in the 
dialysis group as compared to the non-dialysis group; (3) sleep quality was lower in the 
dialysis group; (4) depression was more common in the dialysis group; (5) female gender 
and depression were associated with lower sleep quality; (6) patients with low MCS 
scores indicated high risk for impaired sleep, sleep apnea, and depression; (7) high PCS 
and MCS scores were associated with high Hb and eGFR levels; (8) sleep apnea was 
associated with high BMI and MAP levels; (9) females were 2.5 times more likely to 
have poor sleep quality; and (10) CNS medication use was associated with impaired 
sleep.   
In the dialysis group, eGFR, Hb, Hct, albumin, and Ca values were significantly lower, 
whereas PTH and P values were higher as compared to the non-dialysis group. The above 
differences are as expected for these subgroups. As kidney function declines, P is 
increased due to reduced renal clearance.
54
 As a result of increased P and reduced vitamin 
D and calcium, a rise in PTH is also expected. Due to malnutrition and chronic 
inflammation related to uremic toxins and exposure to artificial membranes during 
hemodialysis, low albumin levels are also expected in the dialysis group.
253,254
 Albumin 
loss through dialysis membranes has also been reported.
254
 Erythropoietin secretion is 
decreased as a result of reduced functioning kidney units, with a subsequent decline in the 
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number of red blood cells.
255
 Due to uremic conditions, the life span of erythrocytes was 
also reduced.
256
 Hb values in the dialysis group would be in part maintained by 
erythropoietin, which would be less commonly used in the non-dialysis group.  Overall, 
anemia and bone mineral metabolism disturbances are very common problems in dialysis 
patients.
257
  
We found that age was not an independent factor for sleep quality in CKD patients (OR: 
1.004, 95% CI: 0.98–1.02, P: 0.59). The correlation between age and sleep quality has 
been studied in CKD patients, with mixed results. Similar to our findings, age was not a 
significant factor for sleep quality in dialysis patients, according to a previous report.
205
 
Monterrosa-Castro et al. studied a total of 1078 middle-aged women for sleep quality and 
indicated that age was not associated with sleep quality.
258
 In contrast, it was reported that 
age was an important factor for sleep quality in PD patients (r: 0.21, P: 0.01).
259
 This was 
supported in another study that included a total of 212 CAPD patients using the PSQI (r: 
0.34, P < 0.001).
177
 The mixed results regarding the effects of age on sleep quality might 
be attributed to the difference in the study populations. We included CKD patients, while 
other studies included only dialysis patients. 
Although age was not associated with poor sleep quality in our report, it was correlated 
with sleep apnea and depression. Those who were at high risk for sleep apnea and 
depression were significantly younger than the low-risk group. Similarly, younger 
patients were more prone to depression in another CKD cohort (P < 0.001) .
221
 In 
contrast, other previous reports found higher age to be a predictor for sleep apnea in the 
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general population.
260
 In the general population, as people get older, the risk becomes 
higher for sleep apnea. In the CKD population, the risk is higher if patients are young. 
Our results showed that female gender was associated with a higher likelihood for poor 
sleep quality (OR: 2.5, 95% CI: 1.5–4.3, P: 0.0001). Parallel to our findings, Huang et al. 
indicated that female gender was associated with poor sleep (OR: 1.54, 95% CI: 1.23– 
1.92, P: 0.001).
261
 Contrary to these, it was indicated that gender was not associated with 
sleep quality in dialysis patients.
262
 These findings were supported in another report (P: 
0.35).
263
 Additionally, gender was not associated with sleep quality in children and 
adolescent CKD patients, according to the report from Davis et al.
264
 Different study 
results in relation to gender and sleep quality are likely due to differences in the study 
populations. The PSQI was employed for the assessment of sleep problems, excluding the 
report by Davis and others, which employed the Pediatric Sleep Questionnaire.
264
 The 
reports were all cross-sectional designs. 
We found that those who were using a CNS medication had a 3.1-fold increased risk for 
poor sleep quality (OR: 3.1, 95% CI: 1.8–5.5, P: 0.0001). In a previous report that 
included 909 incident dialysis patients, benzodiazepine use at the initiation of dialysis 
was shown to be a significant predictor for poor sleep quality (OR: 0.57, 95% CI: 0.39–
0.82).
265
 Poor sleep might lead to prescription of hypnotic agents and reverse causality. In 
another large study, it was shown that CKD patients that sleep less than seven hours per 
night were more likely to use a sleeping pill as compared to those reporting equal to or 
more than seven hours of sleep a night (55.7% versus 36.6%, P: 0.002).
266
  Additionally, 
benzodiazepine use was not significantly different between HD patients and healthy age- 
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and sex-matched controls, according to another report (8.7% versus 4.4%, P: 0.3).
267
 A 
total of 10 (21.7%) patients were reported as benzodiazepine or antidepressant medication 
users in the same study.
267
  Hypnotic or antidepressant treatments were prescribed in 94 
(31%) patients in our study group.  Overall, study results indicated a high prevalence of 
benzodiazepine use in kidney patients in response to the patients’ sleep-related 
complaints.  
Our study indicated that the mean of some of the scales (PF, RP, and VT) and the PCS 
summary measure of the SF-36 was lower than the US normative data in the study cohort. 
Values lower than the general population mean are expected in CKD patients. 
Additionally, higher scores in the non-dialysis group due to a higher level of kidney 
function are also expected. Quality of life was previously tested in the CKD population. A 
total of 30 patients with nephrotic syndrome were studied for quality of life. It was shown 
that only social functioning was significantly lower than the normative data for the 
Japanese population.
268
 Quality of life was not different between HD and PD patients, 
according to a previous report.
269
  
Quality of life summary scales were also tested for an association with sleep quality. In 
our study, we found that the MCS domain of SF-36 was correlated with sleep quality, and 
the most prominent effect was seen when comparisons were made between the highest 
percentile group and the lower percentiles (OR: 0.3, 95% CI: 0.2–0.6, P: 0.001). We also 
found that the PCS and MCS scores were negatively correlated with the total PSQI scores 
(r: -0.16, P: 0.006 for PCS and r: -0.28, P: 0.0001 for MCS). These findings were 
supported by previous studies. Guney et al. indicated that PCS and MCS scores were 
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inversely correlated with the global PSQI score (r: -0.41, r: -0.39, P < 0.001 for PCS and 
MCS scores, respectively).
259
 Similarly, it was indicated that PCS and MCS scores were 
associated with sleep quality (r: -0.45, P < 0.001, r: -0.41, P < 0.001 for PCS and MCS 
scores, respectively).
240
 Further, impaired sleep quality was shown to be correlated with 
low PCS and MCS scores in another study.
265
 The positive correlation between sleep and 
life quality indexes is an expected finding due to possible effects of sleep on physical and 
mental wellbeing. Reverse cause is also possible with those having physical or mental 
problems finding it harder to sleep undisturbed. Moreover, screening tools for both 
conditions have some overlap.  
We reported that abnormal blood pressure and sleep quality were not related in our 
logistic models (P: 0.2 for hypertension and P: 0.4 for hypotension). However, MAP and 
PP were significantly higher in the dialysis group, when compared to the non-dialysis 
group. Further, in our study, we did not find any significant correlation between SBP and 
DBP with sleep impairment. Similarly, Ji-Rong et al. studied a total of 660 elderly people 
for the association between hypertension and sleep quality using the PSQI.
270
 It was 
indicated that sleep quality was not associated with hypertension.
270
 Hung et al. studied 
the association between sleep quality and metabolic syndrome, including hypertension 
using the PSQI in a population-based study.
261
 It was reported that hypertension was not 
correlated with poor sleep quality (OR: 1.03, 95% CI: 0.88–1.21, p > 0.05).261 These 
findings were also consistent with a previous report by Jennings and others.
271
 In contrast, 
several studies reported that there was an association between non-dipper status, which is 
defined as blood pressure drop less than 10% during sleep, and sleep quality being tested 
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with the PSQI, although we did not assess dipping status in our study cohort. Firstly, 
Yilmaz et al. indicated non-dippers had a higher likelihood of being poor sleepers (OR: 
2.95, 95% CI: 1.12–7.74).272 Erden et al. supported that the non-dipping status and the 
PSQI global score were associated (OR: 0.84, 95% CI: 0.74–0.94).93 Huang et al. 
indicated that non-dippers were more likely to have a poor sleep quality (OR: 2.78, 95% 
CI: 1.65–6.87).94 All the aforementioned studies included only hypertensive patients. The 
correlation between SBP and DBP with the global PSQI scores was reported by Fiorentini 
(r: 0.55, P < 0.001 for SBP and r: 0.46, P < 0.001 for DBP).
273
 The study cohort included 
a total of 250 patients who were referred for ambulatory blood pressure monitoring, and 
the prevalence of hypertension was 53%.
273
   
Furthermore, Castro et al. studied a total of 1078 middle-aged women in a cross-sectional 
study for sleep quality using the PSQI.
258
 Hypertension was indicated as an independent 
predictor for poor sleep quality (OR: 0.56, 95% CI: 0.09–1.90, P: 0.019).258 Finally, it 
was reported that low sleep duration and sleep quality have been associated with an 
increased risk for hypertension in a review by Palagini and others.
274
  
In addition to the adult population, adolescents were studied for the correlation between 
sleep quality and hypertension.
275
 This cross-sectional study involved a total of 3372 
students.
275
 Values equal to or higher than 135/85 mmHg were considered as indicating 
hypertension, and sleep quality was assessed using the PSQI.
275
 Poor sleep quality was 
correlated with high BMI measurements and high systolic blood pressure readings.
275
 
Overall, the predictive value of blood pressure for sleep quality in the non-CKD 
population has not been well studied, although it was studied with mixed results in the 
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general population. The data in general support the association, while this study failed to 
show the same effect, which might be due to limitations about this study. Patients were 
classified based on one blood pressure measurement and no adjustments took place for 
presence or absence of blood pressure medications in our study. 
Our findings indicated that the presence of diabetes mellitus was not an independent 
predictor for poor sleep quality (OR: 1.14, 95% CI: 0.72–1.82, P: 0.57). The rate of 
diabetes did not differ between poor sleepers and good sleepers in our study (48% versus 
45%, P: 0.5). The prevalence of diabetes in those with impaired sleep was previously 
studied. It was reported that diabetes was more common in those with high PSQI global 
scores (14.9% versus 8.8%, P < 0.001).
273
  
Further, our results indicated smoking was not related to sleep quality (OR: 1.67, 95% CI: 
0.77–3.6, P: 0.19). Contrary to our findings, smoking has been  associated with poor sleep 
quality, according to a previous report (OR: 1.33, 0.75–1.90, P < 0.0001).258 The odds 
ratio in our study was higher, although it was not significant. The difference might be 
related to the power of the study, which was affected by the sample size and the 
proportion of smokers. The sample size in the report by Monterrosa-Castro
258
 and others 
was 1078, whereas it was 303 in our study. Additionally, the confidence interval in our 
study was wider than the other study, and both confidence intervals were overlapping. As 
a result, it was not possible to distinguish both studies. Our findings might suggest 
smoking was correlated with sleep quality, although we did not reach a statistically 
significant result. Additionally, current smoking status was correlated with sleep quality 
in a cohort of incident dialysis patients.
265
 History of tobacco use was reported as 56.5% 
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in a HD patient cohort by Unruh et al.
267
 We only had a total of 28 (9%) current smokers 
in the entire cohort. The small number of cases might make it difficult to detect any 
relation between smoking and sleep quality.  
We have demonstrated that BMI was not associated with poor sleep quality (OR: 0.99, 
95% CI: 0.96–1.03, P: 0.88) in the study cohort. Similarly, it was reported that the PSQI 
global score was not correlated with BMI.
272
 In contrast, poor sleep quality was shown to 
be correlated with high BMI in the adolescent population without CKD.
275
 The PSQI 
global score was not correlated with IWG and dialysis vintage in our study (P: 0.7 for 
IWG and P: 0.8 for dialysis vintage). Previously, Araujo et al. also failed to show a 
relationship between IWG and sleep quality (P: 0.9).
263
 
We reported a significant association between the PCS and MCS scores with hemoglobin 
in the study cohort (r: 0.32, P: 0.0001 for PCS and r: 0.11, P: 0.05 for MCS). The 
significance was borderline and about 1% of variance in MCS explained by Hb. The 
relationship of hemoglobin with SF-36 summary measures was previously examined. It 
was shown that fatigue and vitality scores were improved after correction of anemia in 
CKD patients (1.21 versus -2.31, P: 0.036).
239,276
 Similarly, it was indicated that the 
treatment of severe anemia was associated with improved quality of life and reduced 
transfusion requirements.
277
 However, complete correction of anemia has been linked to 
several adverse health outcomes such as strokes and cardiovascular events (12 versus 
4).
239,276
 In the same cohort, quality of life scores were later compared between the 
groups.
239
 It was indicated that fatigue scores were improved significantly in the higher 
target arm (3.2 to 7.9, P: 0.007).
239
 Thus, renal anemia management requires careful 
 
 
110 
 
consideration of the pros and cons of the treatment, and hemoglobin levels need to be 
maintained in a narrow therapeutic range. 
The present results demonstrate that eGFR as a continuous variable was not a significant 
determinant for sleep quality in our study cohort, (OR: 0.99 per 1ml/min difference in 
eGFR, 95% CI: 0.98–1.006, P: 0.28). This finding was supported by a previous report. 
Roumelioti et al. studied a CKD cohort, which included children and adolescents, to 
relate eGFR with fatigue and sleeping problems (n: 301).
278
 It was indicated that child 
reported sleeping problems were not significantly different in those with eGFR < 
30ml/min/1.73m², when eGFR ≥ 50ml/min/1.73m² was the reference category (OR: 0.93, 
95% CI: 0.46–1.90).278 Contrary to these, inadequate sleep has been associated with the 
severity of kidney dysfunction, according to the report by Plantinga and others.
266
 In our 
study, the association between eGFR and sleep quality was not statistically significant, 
however 1% change in odds for poor sleep per ml/min change in eGFR may be important.  
Our results did not show any significant correlation between the prevalence of sleep 
apnea and stages of kidney disease (P: 0.3). Similar results were indicated by Plantinga 
and others, in a large study cohort (n: 9,110).
266
  Contrary to these findings, the CKD 
status was indicated as an independent predictor for sleep apnea, when compared to 
normal kidney functions (OR: 1.32, 95% CI: 1.13–1.55 for those with eGFR 15–
29ml/min/1.73m²).
279
 The International Classification of Diseases (ICD-9) diagnosis 
codes for sleep apnea were used to identify the absence or presence of sleep apnea in this 
study.
279
 The ICD-9 diagnosis codes include insomnia or hypersomnia with sleep apnea, 
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and might include more major cases as compared to diagnosis of sleep apnea using the 
BQ.  
In our study, sleep apnea was not associated with dialysis status (P: 0.37). The gold 
standard for sleep apnea is a sleep study. Since we employed the BQ for the risk 
assessment, the relationship might be obscured by false positive or false negative 
questionnaire results. Further, the applicability of the BQ to CKD patients, especially in 
dialysis patients might be questionable. Because of the high rates of physical symptoms 
due to the chronic uremic condition in CKD patients, it is hard to rely on wake-time 
sleepiness and fatigue to identify sleep apnea. As a result, high false positive rates are 
expected. 
Additionally, female gender and low MCS scores were correlated with poor sleep, as 
previously indicated by several reports. In regards to kidney damage, we indicated that 
eGFR was correlated with quality of life index scores. Quality of life was also associated 
with the degree of anemia. All of these are in support of current knowledge. 
Overall, most of our results were consistent with previous reports. We hypothesized that 
sleeping problems and depression correlate with the degree of kidney dysfunction and 
hypertension, and these conditions might affect quality of life in CKD patients. eGFR was 
correlated with depression, but not with sleep quality.  We hypothesized that the 
prevalence of impaired sleep, sleep apnea, and depression would be higher in the group 
on dialysis than in those with less severe CKD. Poor sleep and depression were more 
common in the dialysis group, whereas sleep apnea did not differ between groups. We 
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hypothesized that sleep quality would be correlated with eGFR, blood pressure, and the 
presence of diabetes, but our data did not support this hypothesis. We hypothesized that 
impaired sleep quality, sleep apnea, and depression would be associated with poorer 
quality of life, and this was supported by our data. 
Some findings were different from others, and probably due to the differences in the 
study populations, assessment methods, and by chance alone. We did not show a 
significant correlation between blood pressure parameters (SBP, DBP, MAP, and PP) and 
sleep quality. Several previous reports using ambulatory blood pressure monitoring 
indicated that blood pressure and dipping status were associated with impaired 
sleep.
272,93,94
 We measured blood pressure on one occasion, which might make it difficult 
to identify any possible correlation between sleep and blood pressure. Moreover, sleep 
apnea was not associated with degree of kidney dysfunction. This finding is not consistent 
with a previous report,
279
 and a lack of an actual sleep study for sleep apnea diagnosis in 
our study might be the reason.  
5.2 Strengths of the Study  
 
This study has several strengths that need to be noted. Firstly, the sample size was large 
enough to accommodate patients with various levels of kidney dysfunction. As a result, 
comparisons were made between different stages of CKD. Furthermore, blood pressure 
was measured using an automated device, which reduced the risk for measurement bias. 
Additionally, race may be a confounder in various patient outcomes. This present report 
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is not biased by an effect of race since a total of 99% of the study cohort was Caucasian; 
therefore, the results might be applied to other Caucasian populations with CKD. 
Other strengths of the study include methods related to administration and scoring of the 
instruments. All interviews were performed by the principal investigator, which reduced 
the chance of interobserver errors. However, there was still a risk for measurement bias, 
especially when leading the participant to answer the questions. Further, all 
questionnaires were administered on one occasion, and scored by the same person who 
was blinded to the level of kidney dysfunction, excluding the dialysis group at the time of 
the interview. As a result, interobserver errors were eliminated completely, although other 
potential biases such as observer-expectancy effect might have occurred due to 
involvement of the principal investigator in the interview process. Additionally, SF-36 
questionnaire was scored by the software which decreases the likelihood for incorrect 
calculation.  
5.3 Limitations of the Study 
 
There are several limitations to this study. The common drawbacks of cross-sectional 
studies also apply to the present report. First of all, since it is a cross-sectional study, 
inference of causality is not possible. Therefore, we only tested associations of sleep 
problems and depression. Further, the study would be more prone to biases, such as 
selection bias due to convenience sampling and information bias, because of reduced 
control over external sources. Since we collected most of our data from questionnaires, 
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this study was prone to information bias. For example, social desirability might affect the 
respondents' answers to some questions. 
Additionally, we had only seven cases on PD treatment, although the study included a 
large number of patients. Therefore, it was not possible to assess the difference between 
dialysis modalities. We also had 18 patients with a kidney transplant, limiting inferences 
for this subgroup. Moreover, some analyses yielded wide confidence intervals suggesting 
precision of these estimates might lack power. 
One of the settings for the questionnaire administration was in the outpatient clinics, and 
some patients did not agree to participate as they would have needed to spend extra time 
to answer the questionnaires. This might have posed a risk for a respondent bias. 
Completeness of data for all variables varied, as previously discussed. Moreover, the 
potential for data to be missing from the charts regarding medication use might lead to 
misclassification, and was another weakness of the study.  
Alcohol utilization, opiate use, and comorbidities such as malignancy, peripheral artery 
disease, and coronary artery disease were also not included in this study. Accuracy was 
one of our biggest concerns. The information related to comorbidities was not reliable. 
The medical record would need to explicitly indicate the presence or absence of each co-
morbidity of interest to make the analyses reliable, and that was not the case in this 
retrospective part of the dataset. We were only able to verify accuracy of information 
related to diabetes mellitus. Information related to albuminuria, as well as opiate and 
alcohol use was not consistently available either. As a result, we decided to only focus on 
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certain parameters when we designed the study and wrote the protocol. Thus, some 
relevant information had to be left due to unavailability and/or inaccessibility of the data.  
Another limitation was the absence of a sleep study and structured clinical interview, 
which are the gold standards for diagnosis of sleep quality and depression, respectively. 
Thus, having a strong conclusion is not permitted without a higher degree of certainty 
about the diagnosis. Further, blood pressure measurement was arbitrary as a single value 
might not represent the full spectrum of possible fluctuations. 
There were also several problems with the questionnaires. Firstly, most of the patients, 
especially those on dialysis treatment, exhibited diminished aptitude for reading. As a 
result of reduced attention and concentration functions, reading comprehension can be 
suppressed in kidney patients. Thus, the applicability of questionnaire-based studies can 
be restricted in kidney patients as a result of a lack of interest in completing pen-and-
paper responses. In such cases, an interview was employed to collect data. During the 
interviews, socially acceptable answers might have been given rather than completely 
truthful answers and thus there was an increase in the likelihood of information bias. 
Furthermore, patients preferred to skip several questions in the BDI. There was not a 
regular pattern in the skipped questions, which may have led to a systematic bias. All 
unanswered questions were considered as equivalent to an answer of no. As a result, we 
had very few positive depression cases (9% in the study cohort using the BDI-FS), and 
we reported low depression rate. This may not be an accurate reflection of the reality, and 
we might miss some positive cases for depression. However, our prevalence was 
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consistent with a previous report in CKD patients by Feng and others (n: 364, prevalence 
of depression: 13%).
280
 Further, a general health-related quality of life scale was 
administered in this study. Since disease-specific domains were not included, some 
important information may be missing related to specific effects of kidney disease on 
daily life.  
5.4 Implications for Practice 
 
The prevalence of sleep problems and depression are higher in kidney patients as 
compared to the normal population.
197,221
 These conditions have been related to lower 
quality of life and survival rates both in the general population and CKD patients.
199-202,221
 
Our results indicated a high burden of sleep disturbances in kidney patients, while 
depression prevalence was 9% using BDI-FS as a screening tool. Kidney dysfunction, 
particularly the need for dialysis, was related to quality of life and depression. Since life 
expectancy is already significantly reduced in CKD patients, all appropriate measures to 
improve longevity and quality of life should be considered in the management of these 
patients.  
In our experience, the PSQI was easy to use to evaluate sleep quality. Due to the high 
burden of sleeping disturbances in kidney patients, it can be an acceptable instrument in 
clinical practice for those with sleeping problems. Since our results indicated that the 
dialysis population had higher global PSQI scores than the non-dialysis group, detailed 
and diligent history-taking for sleep-related issues are required in the dialysis patients.  
In addition to sleep evaluation, it was suggested that the PSQI could be used as a 
screening tool for cardiovascular risk assessment in the general population.
273
 However, 
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there is not sufficient evidence to support a direct correlation between the global PSQI 
scores and patient outcomes. The associations are even less clear in kidney patients.
205
 As 
a result, the application of the PSQI as a screening tool to predict cardiovascular risk 
and/or sleep quality might be labour intensive, futile, and cumbersome as a routine 
practice. 
Further, one of the most common causes of poor sleep is sleep apnea, and it is prevalent 
in CKD patients.
197
 A high-prevalence rate of sleep apnea was also consistent with our 
findings, but the causality may not be inferred as this was a cross-sectional study. Sleep 
apnea has been associated with adverse short-term consequences, such as accidents, and 
long-term consequences, such as cardiovascular events.
92,107,281
 As cardiovascular event 
rates are already high in CKD patients, a comprehensive approach to reducing the risk 
should be employed. Evidence suggests that CPAP treatment for sleep apnea reduces 
cardiovascular events and mortality.
282
 Similarly it was indicated that CPAP was 
associated with improved longevity and quality of life in kidney patients.
283
 However, 
cost and patient acceptance may reduce the uptake of CPAP therapy. Moreover, sleep 
apnea has been associated with depression in our study. A detailed history should be 
taken in all depressive CKD patients to diagnose sleep apnea, as it might be a correctable 
underlying contributor to depression.
283
  
Although it is important to recognize and manage sleep apnea due to its link to depression 
and increased rates of cardiovascular incidents, diagnosis of sleep apnea might be 
challenging because of atypical presentation and a lack of highly validated tools for 
screening purposes in kidney patients.
43
 The BQ is a validated tool for sleep apnea in the 
general population.
17
 Nevertheless, the instrument might be associated with frequent false 
 
 
118 
 
positive responses in dialysis patients due to the second component of the questionnaire, 
which measures wake-time sleepiness and fatigue. The second component is considered 
positive in those with fatigue after sleep at least three or four times per week. This is a 
common finding, especially in HD patients probably due to the intermittent nature of the 
treatment and the associated rapid changes in the blood parameters.
284,285
  
Depression is a mental state of feeling guilty, punished, and like a failure, and is 
associated with an exacerbating self-criticism.
136
 People might seem very friendly and 
nice to others even when they are severely depressed. Physicians who only rely on their 
clinical judgment without the standard clinical interview or a screening tool for 
depression might underdiagnose the condition, which may be life-threatening in the case 
of suicide.
251
 Given the high prevalence in CKD patients, it is important to assess patients 
at least semi-annually as recommended by the KDOQI guidelines.
64
 Recognition and 
management of the condition may improve patient satisfaction and quality of life, 
although safety and effectiveness of antidepressant treatment in CKD patients is 
controversial.
232
 In our experience, we recognize the BDI-FS as a brief and easily 
administered method for depression screening as it only questions the mental state of the 
patients. The BDI has questions related to both physical and mental components. As a 
result, the BDI is more time-consuming and might be misleading due to the effects of the 
uremia on general physical wellbeing. 
Lastly, defense mechanisms are unconscious coping systems that work to reduce the level 
of anxiety for an unacceptable impulse.
286
 Denial is one of the defense mechanisms that 
might lead to reality distortion by ignoring the problem.
286
 Patients who have chronic 
health conditions might use the denial defense mechanism when they are incapable of 
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accepting the problem.
287
 When a question is posed regarding their physical and mental 
capability, the defense mechanism is destroyed as the unconscious state is cancelled out. 
As a result, the patient may recognize and accept the problem at that point. If the direction 
of the treatment is not expected to be changed according to the results of the 
questionnaire, it might not be beneficial to apply the tool, especially to those patients with 
irreversible conditions. 
To conclude, the PSQI might be employed in those with sleep disturbances, especially in 
dialysis patients. The BDI-FS is a practical and valid tool to evaluate depression, and can 
be used in kidney patients annually or semi-annually. The BQ is validated for sleep apnea 
screening in the general population;
17
 however, it might not be a reliable instrument in 
dialysis patients. One of the components of the BQ assesses day-time functioning, which 
can be affected by uremic toxins.
284,285
 SF-36 is a valid tool, but the results do not affect 
the practice pattern in CKD patients most of the time. Thus, it needs to be employed in 
selected cases with careful consideration of its possible negative emotional impact on 
patients.  
Overall, screening for depression and evaluation of sleep disorders in symptomatic cases 
are important in CKD patients. Although the effectiveness and safety of antidepressant 
treatment is not clear in kidney patients, antidepressant therapy, anxiolytic therapy, and 
hospitalization are needed if the patient has suicidal or homicidal thoughts and severe 
depression.
232
 Sleep apnea might be treated efficiently with CPAP.
132,133
 Additionally, 
providing adequate dialysis for solute and fluid removal, and maintaining guideline-
appropriate targets might also be important in the management of sleep problems, 
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including sleep apnea, as well.
288
 Both conditions have been correlated with negative 
patient-oriented outcomes. 
13,113,114,140
 
5.5 Implications for Research 
 
Normal functioning of the hypothalamo-pituitary-adrenal axis is required for resolving 
sleep problems and depression.
117,118,148
 Additionally, the normal state may also improve 
or protect the current kidney functions.
289
 Although the components and interactions of 
the system are extensively studied, there are still poorly understood aspects that deserve 
further investigation. 
Sleep is a valuable avenue to explore and understand the complex function and structure 
of the autonomic nervous system and its interaction with the HPA axis. The tools to 
reestablish sympathico-vagal balance are not fully successful at present; however, newly 
emerging techniques to control overactive sympathetic tone are promising, such as 
radiofrequency ablation of renal sympathetic nerves.
290,291
 Further research is needed to 
increase knowledge and experience and to solidify the benefits of the techniques. 
Abnormalities in the functioning of the autonomic nervous system might underlie sleep 
problems, especially sleep apnea and depression.
117,118,142,143
 Novel approaches to 
resetting these systems might be helpful in controlling sleep and mood disorders. 
Exploring the complexity of the relations between poor sleep, sleep apnea, depression, 
and kidney dysfunction requires large-scale studies that employ accepted gold-standard 
tests for diagnosis of the conditions. The association between the components of the 
metabolic syndrome, sleep disturbances, and depression might also accommodate more 
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research in the field. In particular, stronger designs to assess the causality of the observed 
associations are required to inform not only current therapies, but also research into even 
more effective therapies in the future. Although clinical presentations may differ 
substantially, the underlying causal pathophysiological pathways for sleep disturbances, 
depression, and overactive renin angiotensin aldosterone system, which is a major threat 
for kidney function loss, may share common features linked to the autonomic nervous 
system and the HPA axis.
117,118
 Therefore, these factors need to be elucidated in future 
research.
117,118,142,143
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Chapter 6: CONCLUSION 
 
This study tested factors related to sleep quality, depression, and quality of life in CKD 
patients. Sleep quality was not correlated with eGFR, blood pressure, and presence of 
diabetes. Poor sleep quality, sleep apnea, and depression were associated with lower 
quality of life scores. CNS medication use was more common in the dialysis group and 
associated with poor sleep quality. Gender, marital status, risk for sleep apnea, 
depression, and MCS scores were correlated with sleep quality. Age, BMI, MAP, 
depression, and PCS and MCS scores were associated with the risk for sleep apnea. Age, 
gender, and kidney dysfunction were correlated with depression in our study. 
Hemoglobin and eGFR were correlated with both quality of life summary measures. The 
prevalence of impaired sleep and depression were higher in the group on dialysis than in 
those with less severe CKD.  A total of 117 (39%) patients were poor sleepers, while the 
prevalence of depression was 9.4% using BDI-FS. Stage of CKD was not correlated with 
sleep quality, but was with depression. Female gender and either an antidepressant use or 
a hypnotic treatment doubled or tripled the risk for poor sleep quality, according to our 
results. In the non-dialysis group, female gender, being depressed, and low MCS scores 
were related to impaired sleep. In the dialysis patients, on the other hand, a high risk for 
sleep apnea appeared to be tied significantly with sleep quality in addition to female 
gender, depression, and low MCS scores.  
The high prevalence rates of sleep problems and low quality of life scores were similar to 
the findings of others. The findings suggest a need for more robust studies that assess the 
causality of these associations, as well as further work on underlying pathophysiological 
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mechanisms. In the meantime, large-scale studies in CKD patients for predictors of poor 
sleep quality and depression might be recommended. Prospective cohort studies would be 
a reasonable choice to shed considerable light on predictors of both conditions. 
Polysomnography and the structured clinical interview need to be employed to more 
firmly establish the diagnosis of sleep apnea and depression, respectively. In the 
meantime, BDI-FS may be employed in nephrology practice, since depression screening 
is a vital component of the standard care of CKD patients. The PSQI may also be used for 
sleep quality evaluation in symptomatic patients.  
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APPENDICES 
Appendix A: Data Abstraction Form 
 
ID number:                                                                          
 Age:                                    
Race:                                                                     
Gender:                                       
Marital status  
Height: 
Weight 
Smoking:  
Current (Y/N) 
Past or never (Y/N)       
Diabetes mellitus(Y/N):                                                              
Dialysis vintage: 
Vascular access        
eGFR by the MDRD formula 
PTH 
Ca 
P 
Albumin 
Hemotocrit 
Hemoglobin 
Current medications: 
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Sedatives 
Antidepressant 
Blood pressure 
Inter-dialytic weight gain 
Dialysis modality 
The scores form the questionnaires: 
The Beck Depression Inventory 
The Beck Depression Inventory Short form 
The Berlin Questionnaire 
The Pittsburgh Sleep Quality Index 
The SF-36 
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Appendix B: Mechanisms for Sleep Apnea 
 
                                              SLEEP APNEA 
 
           Obstructive sleep apnea                      Central sleep apnea 
                        
                          Obstruction 
 
Incomplete opening             Mechanical obstruction 
            Muscle dysfunction                                                         
                                     Congenital                Acquired 
  
                                                           Excessive fluid Excessive fat tissue 
Structural abnormalities                    Hypervolemic states               Obesity 
  
 
                Congestive heart failure and CKD 
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Appendix C: Flowchart for Pathogenesis of Depression 
 
                                 Reduced Glutamic acid decarboxylase (GAD) 65 and 67  
 
                               Reduced   Gamma Amino Butyric acid (GABA) 
  
 
                                Increased   Corticotrophin Releasing Hormone (CRH) 
                                    [Overactive hypothalamic-pituitary-adrenal axis] 
 
                                                              
                                   Increased     adrenocorticotropic hormone (ACTH) 
                                Adrenal cortex           Adrenal medulla  
 
                                           Glucocorticoids  increased      NE and E increased:
292 
                                                                                                                                     Increased blood flow in adrenals 
                                                                                                                                     Increased direct secretion of NE and E 
                                                                                                                                   
Increased tyrosine hydroxylase and dopamine 
beta- hydroxylase 
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Appendix D: Diagram for Normal Sleep 
 
 
 
 
                                               Sleep 
  
                      
 
 REM NREM 
                                                                         
  
Tonic REM   Phasic REM                            Stages 1, 2, 3 and 4  
